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Abstract 
 Autism is a childhood neurodevelopmental and psychiatric disorder that involves 
the impairment of social skills and communication. The genetics behind the inheritance 
and susceptibility of this disorder are not well known but have recently been studied. 
Lately, DNA Copy number variation (CNV) in autistic individuals has been a topic of 
high interest, and has been shown to have an association with this disorder. CNV 
generally refers to differences in the germ line DNA content between individuals. CNVs 
span from 1-kb to multi-megabases, and represent a significant portion of genetic 
variation in normal humans. Significant work has been done in the field of Autism 
Spectrum Disorder (ASD) genetics to find CNVs implicated in the development of 
autism and the variation of phenotype. In order to identify new disease alterations, we 
are conducting CNV discovery studies on 10 autistic children and their families. We 
expect our findings will lead to a better understanding of pathophysiology and to new 
avenues of therapeutic treatment. We conducted CNV discovery in 10 autistic children 
using array Comparative Genome Hybridization (aCGH) on a tiling-resolution whole 
genome BAC microarray. This platform can detect CNVs >50-kb. From the high 
confidence CNV calls (based on standard deviation and signal-to-noise Ratios), we 
filtered out all variants that are found in 4% or more of normal individuals. We have 
identified over 100 high confidence candidate CNVs that have rarely or never been 
reported previously. In addition, we have begun to determine if any variants were 
created de novo in the affected child (i.e., were not inherited from parents). Some 
candidate de novo variants span many genes and could have functional effects. We 
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conclude that it is worth conducting more genome-wide CNV discovery in autism, and 
testing suggestive CNVs for association in large numbers of autism patients. 
Introduction 
Overview of Genomic Variation 
Genomic structural variation is an all-encompassing term used to group genomic 
alterations involving segments of DNA that range in size from single nucleotide 
alterations to entire losses of chromosomes (Fig. 1). This variation may be based on 
orientation, position, or quantity of DNA segments. The more closely-related humans 
are, the more similar their genomes and their variations. However, it has been 
estimated that the genomes of non-related people differ at about 1 in every 1,200 to 
1,500 DNA bases, (Eenennaam 2008) creating more than three million differences 
between these two individual genomes. This discrepancy is mainly due to smaller 
genetic variations known as single nucleotide polymorphisms or SNPs (Scherer et al. 
2007). 
The majority of genomic variations deal with relatively small alterations involving 
only a few bases. However, larger variations have been found in normal individuals that 
have no current disease implications. Many studies are analyzing larger numbers of 
normal individuals from different backgrounds to identify the variations between 
individual genomes that exist.  However, due to the large numbers of possible genomic 
variations and the current platforms available to study variation, it remains a difficult, 
expensive, and time-consuming endeavor.  Although it has been found that 99% of 
human DNA sequences are the same, the variation in the sequence can have a vital 
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role in human response to disease and to environmental factors as well as 
pharmaceutical therapies.   
 
Figure 1 List of genetic variation found in humans.  In a broad sense, structural variation has been used 
to refer to genomic segments both smaller and larger than the narrower operational definition, as 
illustrated by the large bracket. The focus of recent discoveries has been the subgroup in the midrange 
(indicated with strong highlighting), but the gradation of shading illustrates that the biological boundaries 
may really encompass some forms of variation previously recognized from either cytogenetic or molecular 
genetic approaches (Scherer et al. 2007). 
 
Genomic variations can be found in all areas of the genome, including coding 
and non-coding gene regions. However, this variation is not distributed evenly through-
out the genome. Various parts of the genome known as "hot spots" have a much higher 
chance of variability than others. Additionally, there are “stable” regions of the genome, 
which do not vary to a great extent between individuals and are said to be highly 
conserved throughout the species. Furthermore, the sizes of a structural variation have 
variable effects on the expression of genes. However, the effect is dependent on the 
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region in question.  For example, an alteration in a very active and critical gene region 
which is necessary for life will have adverse effects despite size variability.  
Forms of Structural Variation 
There are many specific forms of genomic variation that have been classified and 
are known to be involved in altering genetic expression. One form of genomic structural 
variation that makes up approximately 90% of all human genetic variability is called 
single nucleotide polymorphism (SNP) (Scherer et al. 2007). SNPs are sequence 
variations that occur when a single nucleotide in the genome sequence is altered. 
However, in order for such a change to be called a polymorphism it must be found in at 
least 1% of the population. Over the entire human population, SNPs occur every 100 to 
300 bases along the 3-billion-base human genome (i.e., more than 2 million SNPs) 
(Thorisson et al. 2003). The majority of SNPs are presumed to have no effect on cell 
function and are typically the replacement of cytosine with thymine, found in two of 
every three SNPs.  SNPs are thought to have originally come about by errors in DNA 
replication or repair that occurred once in human history and are now shared among 
individuals by descent (Hinds et al. 2006). In addition, some SNPs have been found to 
have biological effects or to be associated with disease or drug responses. 
Another form of genomic variation which is slightly larger in size are variable 
number of tandem repeats (VNTRs). VNTRs are a repeated sequence of DNA that tend 
to occur in non-coding DNA. Examples of VNTRs are microsatellites and minisatellites. 
In some VNTRs, the repeated unit may occur in differing numbers from 10 - 100 times. 
The repeated sequence is often simple, consisting of two, three, or four nucleotides. 
Cytosine and Adenine nucleotide repeats are very frequent in humans and are present 
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every few thousand base pairs (Blouin et al. 1996).  There are usually many alleles 
found in VNTR regions, and the original allele from a parent can often be identified 
using VNTRs as markers. Due to this trait of VNTRs, they can be used in a multitude of 
applications such as determining paternity, population genetic studies and 
recombination mapping (Dakin et al. 2004). VNTRs have an increased rate of mutation 
compared to other neutral regions of DNA and are most frequently explained by slipped-
strand mispairing, which is the mispairing of the complementary bases during DNA 
replication on a single DNA strand. VNTRs are structural variations which are found in 
normal individuals but are also found in individuals with disease. For example, 
Huntington’s disease can be seen to be associated with a trinucleotide VNTR of CAG 
which repeats over 28 times (MacDonald et al. 1993). Studying these variations may 
help find additional genetic implications to various disorders and diseases. 
DNA Copy Number Variation 
Copy Number Variation (CNV) refers to larger genomic variation which represent 
a copy number change involving a DNA fragment that is ~1 kilobases (kb) or larger in 
germ line DNA(Redon et al. 2006). DNA copy number alterations have long been 
associated with specific chromosomal rearrangements and genomic disorders. The 
extent of this variation is still under investigation and it seems likely that in humans, 
CNVs account for a substantial amount of genetic variation. Approximately 4000 genetic 
loci are currently mapped on The Database of Genomic Variants (DVG) 
(http://projects.tcag.ca/variation) (Korbel et al. 2007). CNVs have been found to account 
for almost five times greater the variation than SNPs in the number of affected bases 
(de Smith et al. 2008). CNVs can occur in genic regions and can result in differential 
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levels of gene expression. Therefore, CNVs may account for a large proportion of 
normal phenotypic variation in the genome (Freeman et al. 2006). There are currently 
800 CNVs which occur normally in humans (Korbel et al. 2007). 
Until recently, the majority of structural variation was observed as segmental 
duplications or specific gene disorders (e.g., Lupski 1998; Ji et al. 2000; Inoue and 
Lupski 2002; Stankiewicz and Lupski 2002). In addition, they were thought to be 
primarily found in heterochromatin and repeat-rich areas which may not affect an 
individual’s genetic expression. However, two landmark studies found that some large 
duplications may not be related to disease and are found in normal individuals (e.g., 
Barber et al. 1998; Engelen et al. 2000). Building on this work, Sebat et al. (2004) 
showed that there are extensive CNV present in healthy individuals (i.e., have no 
apparent disease association). However, the results were limited by the platforms and 
total number of subjects used. Following this study, another lab, Tuzun et al. (2005), 
found more than 80% of new CNVs were not identified previously. In addition, each 
CNV ranged from 8kb to 40kb which was a much higher resolution than previously 
identified CNVs. This study used a different platform that allowed for the greater 
resolution (Tuzun et al. 2005).  A subsequent study by Sharp et al. (2005) targeted 
known duplicated regions of the human genome which may lead to rapid identification 
of CNVs. This study used different populations of individuals and identified 19 CNVs, of 
which only 39% had been described previously. The authors concluded that CNVs 
shared among several populations meant that specific genomic differences either 
predated the dispersal of modern humans out of Africa or recurred independently in 
different populations (Sharp et al. 2005).   
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More recently, three CNV studies that specifically interrogated human genomes 
for non-disease variants were published concurrently (Conrad et al. 2006; Hinds et al. 
2006; McCarroll et al. 2006). Two of these studies used SNP data generated from the 
International HapMap Project, which characterized human genetic variation in a cohort 
of 269 individuals from different populations. The HapMap Project provided a SNP 
genotype at ~5-kb resolution in each of these 269 samples studied for a total of 1.2 
million SNPs (The International HapMap Consortium 2005). Due to the abundance and 
availability of SNP data  across the human genome, it was thought that SNP data could 
be used to find underlying CNVs by using the results of SNP genotyping assays (The 
International HapMap Consortium 2005; Conrad et al. 2006; McCarroll et al. 2006). In 
the third study 215 potential deletion variants ranging from 70 bp to 10 kb were 
identified (Hinds et al. 2006). A subset of 100 PCR-confirmed deletions was further 
characterized, with 41 of the deletions found to be present among the 24 individuals 
with an allelic frequency of greater than 10% (Hinds et al. 2006). 
Due to the platforms and various procedures used in the past, there are 
discrepancies among the CNV discovery studies. This is based primarily on each study 
having its own bias toward specific types and sizes of CNVs. Using various platforms 
provides differing abilities to detect CNVs depending on their size, sequence class, or 
location.  The high density oligo array used by Hinds et al. (2006) helped to detect 
deletions in a wide variety of sizes.  However, their analysis avoided repetitive regions 
(e.g., segmental duplications) that may be more likely to be associated with larger size 
CNVs (Freeman et al. 2006). The DGV (http://projects.tcag.ca/variation) had an average 
sized CNV of 118kb; however the median size was 18 kb. (Freeman et al. 2006).  This 
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discrepancy, as stated before, is due to the studies done by Conrad et al. (2006) and 
Hinds et al. (2006). These inconsistencies accounted for mainly smaller CNVs; the 
majority being <10 kb (Korbel et al. 2007). Using BAC aCGH methods, the copy number 
variation could entirely encompass a smaller CNV, overlap a CNV, or be totally within a 
CNV that is actually larger than the BAC clone itself. Because of this ambiguity, the size 
of the entire BAC clone is used in lieu of the actual size of the CNV (Freeman et al. 
2006). Since then, there have been a large number of studies which have looked for 
CNVs in normal individuals and individuals with various genetic diseases. This variation 
between normal humans and diseased patients give additional information which can 
lead to disease associations with various gene regions. The progression of discovery 
has moved toward a more comprehensive cataloging and characterization of CNVs; this 
will provide the basis for determining how genomic diversity impacts biological function, 
evolution, and common human diseases. (Freeman et al. 2006).   
 CNVs have been found often in regions of larger homologous repeats or 
segmental duplications (Fredman et al. 2004; Sharp et al. 2005; Tuzun et al. 2005). 
Approximately 5% of the human genome is composed of duplicated sequence (Sharp et 
al 2005). CNVs that are associated with segmental duplications may be susceptible to 
structural chromosomal rearrangements via non-allelic homologous recombination 
(NAHR) mechanisms (Lupski 1998). When segmental duplications are present on the 
same chromosome, they can facilitate changes in CNVs of the segmental duplicated 
regions along with intervening sequences (Inoue and Lupski 2002). NAHR can result in 
the formation of CNVs in normal individuals, in addition to large structural 
polymorphisms and chromosomal rearrangements (Lupski 1998; Ji et al. 2000; 
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Stankiewicz and Lupski 2002; Scherer et al. 2003; Eichler et al. 2004; Shaw and Lupski 
2004; Lupski and Stankiewicz 2005). Approximately 50% of reported variant sequences 
have been found to overlap segmental duplications (de Smith et al. 2008). Some CNVs 
are also found in regions of little segmental duplication. The majority of smaller known 
CNVs are thought to be driven by non-homology-driven mutational mechanisms 
(Freeman et al. 2006). Using DGV, new CNVs which are found in diseased patients can 
be analyzed to see if the CNVs found are indeed disease associated or are CNVs found 
in the normal population (Wong et al. 2006).  
Methods of CNV Discovery 
The ability to detect genetic variation on a genome-wide scale is a relatively 
recent undertaking. CNVs were first observed by using microscopes; however the 
advances in genetics due to the human genome project led to the conception of CGH. 
Array CGH was initially used to identify segmental alterations in specific chromosomal 
regions associated with disease (Solinas-Toldo et al. 1997). The next generation of 
genomic microarrays examined a specific chromosome or chromosome arm. One of the 
first studies looked at a chromosome 20 array containing 22 cosmid, P1 phage artificial 
chromosome (PAC) and bacterial artificial chromosome (BAC) clones as interval 
markers covering chromosome 20 at 3 Mb resolutions (Pinkel et  al. 1998). Although 
CGH studies using regional and chromosomal microarrays have yielded a great deal of 
information, these studies are naturally biased to specific areas of the genome or very 
large alterations (multi-Megabases) and require a prior knowledge of regions of interest. 
To overcome regional bias, genome-wide arrays were developed (Davies et al. 2005 
array CGH).  
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The three main spotting elements used are complementary DNA (cDNA), 
oligonucleotides, and bacterial artificial chromosomes (Ylstra et al. 2006). In the past, 
laboratories had to manufacture their own microarrays which was a very complicated, 
time-consuming, and expensive process. However, recently these microarray slides 
have been commercially manufactured by various corporations, which make this form of 
DNA analysis much simpler and cost effective. 
 The use of cDNA as a spotting medium is not as prevalent due to a variety of 
disadvantages. One clear disadvantage is the low signal-to-noise ratio obtained from 
these spots. The variable signal intensities are also a major concern while using cDNA 
clones as targets for detecting copy-number alterations. In addition, in order to reliably 
detect single copy changes, a moving-average of clone intensities must be calculated, 
thereby reducing the resolving power of the arrays (Davies et al. 2005). Moreover, 
larger quantities (micrograms) of sample genomic DNA are required in order to 
generate a robust signal, thus limiting the utility of cDNA array CGH (Pollack et al. 
1999). 
More recently oligonucleotide aCGH platforms have become available. Oligo 
aCGH platforms generally were single-stranded 25 to 85mer oligonucleotide elements 
on the array. An inherent problem of cross hybridization of oligonucleotide targets to 
multiple genomic loci is the need for complexity reduction of the sample genomic DNA 
(Davies et al. 2005). In order to increase signal to noise ratios, the whole-genome 
sampling assay (WGSA) was developed to greatly reduce the genomic complexity of 
the sample probes by about 98% to improve hybridization kinetics (Davies et al. 2005). 
Hybridization of complexity-reduced probes to SNP arrays is able to detect high-level 
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copy number changes; however, since the resolution of the method is dependent on the 
inconsistent SNP-density on the array, over a fifth of the chromosomes measured were 
inconsistent with the segmental genomic alterations detected by BAC-array CGH due to 
poor SNP representation (Bignell et al. 2004). In addition, the data generated by the 
SNP-arrays showed high variability, probably due to the requirement of PCR 
amplification of genomic sample DNA. This required the use of a moving average to 
detect copy-number changes, further lowering the effective resolution of the method 
(Bignell et al. 2004).  
There are two main commercial oligo aCGH platforms available from NimbelGen, 
and Agilent.  However currently there are higher resolution arrays being manufactured. 
The first commercial oligo aCGH platform is manufactured by Agilent Technologies. 
They created their arrays specifically for array CGH, and include oligonucleotides 
covering intergenic regions. At the time of the current study, the Agilent array platform 
used 244k 60mer oligonucleotides, (very recently the single slide probe density was 
increased to include 1M probes per array).  The direct labeling protocol is similar to the 
one used for the cDNA arrays and requires 1 µg of input DNA, which hampers the use of 
small clinical samples (Barrett et al. 2004). To overcome this problem, an additional 
PCR amplification procedure was developed allowing as little as 10 ng of input DNA. 
Apart from the necessity to do amplifications of test and reference sample(s) in parallel, 
any PCR-based DNA amplification introduces some level of additional variation and 
adds to the overall cost of arrays (Barrett et al. 2004).  
The second oligonucleotide platform is commercially offered by NimbleGen. They 
provide arrays containing 385 K and a new 2.1 M oligonucleotides which are photo-
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lithograhically synthesized on the array. The array production is extremely flexible, such 
that each array produced can have a different set of oligonucleotides on it. The oligo 
aCGH oligonucleotides are designed to be isothermal and vary between 45 and 85 bp in 
length (Ylstra et al. 2006). For their labeling and hybridization procedures, NimbleGen 
adopted essentially the same direct labeling conditions as Agilent and the cDNA CGH 
platforms. Lucito et al. applied an alternative oligo aCGH array method. The method 
called ROMA (representational oligonucleotide micro array analysis) uses a 98% 
complexity reduction of test and reference DNA (Lucito et al. 2003). This is carried out 
by a digestion-amplification step, which allows starting with as little as 50 ng of input 
DNA. For reproducibility, this labeling and amplification procedure requires test and 
reference samples to be amplified in parallel. ROMA combined with the NimbleGen 
array provides a high-resolution alternative that allows low amounts of sample DNA 
input and has already proven its value in the field of human genetics (Ylstra et al. 2006). 
  Different oligo arrays are combined with various labeling and hybridization 
techniques and all yield high-resolution copy number measurements. Yet, none of the 
current oligo aCGH platforms can make a definite call for loss or gain using a single 
oligonucleotide; but rather at least 3–5 adjacent oligonucleotides and preferably greater 
or equal to 10 are necessary for a reliable call. As seen in the literature, there is no “gold 
standard” that has been used to find structural variation. However, each lab uses each 
platform to subsequently provide the most relevant information for their particular study. 
The most widely used aCGH arrays in the past have been based on bacterial 
artificial chromosomes or BACs. DNA yielded for BACs vary in length from 150 to 200 
kb and are generally isolated from Escherichia coli. The DNA is then amplified by PCR 
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prior to spotting the arrays. This is done since high DNA concentration is mandatory for 
high quality results. BAC platforms can be outstandingly sensitive and, in the range of 
50kb-150kb, precise (Ylstra et al. 2006). One can detect a single-copy gain or loss on a 
single arrayed BAC element. Although BAC arrays have relatively few printed elements 
on the arrays compared to oligo arrays, their spatial resolution is high. The higher signal 
compared to oligo arrays, allows for single copy transition boundaries (Ylstra et al. 
2006). The use of BACs also confers high and consistent binding specificity (Pinkel et 
al. 1998; Hodgson et al. 2001), and thus more accurate copy number determination. 
The breakpoint resolution that can be obtained with BAC arrays, however, is finite 
because of their large size (Ylstra et al. 2006). Another variable in array CGH is the Cot-
1 DNA which is used in the procedure to block repetitive DNA sequences in the arrayed 
elements (Pinkel et al. 2005).  Cot-1 DNA is placental DNA and yields variable DNA 
fragments of 50–300 bp in length. Batch to batch variation makes Cot-1 DNA a highly 
variable element in the array procedure. For oligo aCGH, Cot-1 DNA is not necessary, 
since the oligonucleotides are designed to be repeat-free.  
In 2004 the Wan Lam laboratory (BCCRC, Vancouver; Ishkanian et al. 2004), 
published the first sub-megabase resolution tiling-set (SMRT) array that contiguously 
covered the human genome in a tiling path manner. By using overlapping clones, the 
resolution of the array was increased beyond the size of a single BAC clone and gains 
and losses of regions as small as 40–80 kb are detectable. A major advantage of using 
a tiling-path array is in identifying small (gene level) gains and losses. The probability of 
missing a small genetic alteration is inversely proportional to the genome coverage or 
representation of the detection strategy. The tiling path array offers a much greater 
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probability of detecting small-sized alterations (e.g. 40 kb) than marker-based genomic 
arrays. The even distribution of markers throughout the genome, as opposed to having 
a large number of small loci clustered in selected regions, is a key consideration in 
improving the resolution of genomic scanning strategies. The first version of the (SMRT) 
tiling-path array was composed of 32,433 clones spotted in triplicate over two 
microarray slides (Ishkanian et al. 2004). In version 2 of the SMRT array the Lam lab 
has created the SMRT re-array (SMRTr). The SMRTr array contains a more selective 
set of clones representing 83% of the original collection, eliminating unnecessary 
redundancy while maintaining tiling path coverage. As a result, the 27,000 clones are be 
spotted in duplicate, on a single slide, reducing the cost and time of analysis (Ylstra et 
al. 2006). 
 These various platforms have their own distinctive characteristics that can be an 
asset while discovering novel CNVs. When this study was initiated, the use of SMRT 
array with the use of BACs spotted in duplicate has the one of the best effective 
resolutions (comparable to the NimbleGen 385k and Agilent 244k arrays) while using a 
small amount of genomic DNA. Moreover, the SMRT array requires much less DNA, 
400ng compared to 1-2µg. Due to these facts we have chosen to use this platform in 
our study. The SMRT micro array used in our lab contains 26,363 clones spotted in 
duplicate with an effective resolution of 50kb. Although the BAC array used in our lab 
has a weaker breakpoint resolution, they have been able to call 10X more CNVs than 
on similar resolution oligo arrays. This is due to the fact that our array contains non-
unique sequence allowing for a larger number of possible CNVs to be found. The slides 
were printed by the Wan Lam lab at BC Cancer Agency Research Centre in Vancouver, 
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Canada (http://arraycgh.ca/index.php). Our lab is a beta-site for the Wan Lam lab, by 
use of the platform, skills and competency to begin CNV discovery. In addition, the 
quality control and bioinformatics used in our lab was internalized with the help of the 
Wan Lam lab. In Table 1. we show Real Time PCR validation of CNV calls made in our 
lab. The CNVs called in our study are thus high confidence in part by calibration with the 
experimental and analytical methods developed and stringently validated by our 
collaborators (Ishkanian et al. 2005, Wong et al. 2006).  
  In order to validate the methodology of our platform, multiple controls were 
performed. As seen in (Fig. 2.), the visualization of trisomy 21 in individual 4 is quite 
compelling. Essentially all BACs are shifted to the right, confirming the one copy gain of 
chromosome 21 in this individual.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. CNV validation by Real Time PCR. The father in this family transmitted two diseases to children 
from two mothers. CNV discovery was done by aCGH using a reference of DNA pooled from multiple 
individuals. In this Real Time PCR study (delta-delta Ct method, Livak and Schmittgen 2001), CNVs are 
validated between affected and unaffected siblings and compared to a second pooled reference. aCGH 
Page | 17 
 
threshold score is copy number change (Ratio) / standard deviation autosomal (> +/- 2.85 are called 
significant gain/loss) (Chen et al. 2008). 
 
Figure 2. This example illustrates the methodology of the SMRT BAC array platform. Starting from the left 
the green spots represent genes which correspond to genes on the chromosome, then the banding of the 
long arm of chromosome 21. Finally the four panels represent four distinct individuals. The midline 
represents a 1/1 ratio of cye3 and cye5, and any deviation to the left or right suggests a loss or gain in 
copy number respectively. The first three panels show normal individuals who have almost no copy 
number alterations. However, the fourth panel clearly demonstrates a one copy gain of the entire 
chromosome and validates trisomy 21.   
Overview of Autism 
Autism Spectrum Disorders (ASDs) are a group of childhood 
neurodevelopmental and neuropsychiatric disorders characterized by impairments in 
social interaction, verbal communication, and restricted and repetitive patterns of 
interests and behaviors (Wang et al. 2009). Diagnostic tools based on phenotype for 
ASD have been standardized for reliable diagnoses. This was accomplished by the 
release of the Autism Diagnostic Interview-Revised (ADI-R), a parents’ or caregivers’ 
questionnaire, and the Autism Diagnostic Observation Schedule-Generic (ADOS-G), a 
direct testing tool of the patients’ current behavioral pattern. In addition, the diagnostic 
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criteria of DSM-IV have all helped to standardize the diagnosis of ASDs in the world. 
ASDs include a range of clinically defined conditions including autism, Asperger 
syndrome, Rett syndrome (RTT), childhood disintegrative disorder (CDD), and 
pervasive developmental disorder not otherwise specified (PDD-NOS).  
 ASD symptoms are recognized typically within the first 3 years of age with a 
lifelong persistence. Current prevalence estimates in the United States are 0.1–0.2% for 
autism and 0.6% for ASDs (Newschaffer et al. 2007). In addition, it has been found that 
ASDs are about four times more common in boys than girls, and at present around 1 in 
150 children in the United States have a diagnosis of an ASD (Wang et al. 2009). It has 
also been estimated the ASDs collectively affect 60 in 10,000 individuals (Fombonne 
2005).  
In several studies it has been found that ASD susceptibility has a strong genetic 
component. For example there are much higher concordance rates of ASDs in 
monozygotic twins (92%) than dizygotic twins (10%) (Bailey et al. 1995). Autism has 
estimated heritability of greater than 90%. In addition, familial clustering largely is 
explained by genetic factors. Moreover, observations about the patterns of inheritance 
among families, including studies of twins, first-degree relatives, and more distantly 
related individuals, all suggest that ASDs are not caused by the action of a single gene 
transmitted in a simple dominant, recessive, or X-linked fashion. Indeed, the number of 
contributing loci, or genetic regions, has been estimated to be in the neighborhood of 15 
(Risch et al. 1999; Gupta et al. 2006). Several diagnosable medical conditions show 
symptomology of autism spectrum disorders as well (e.g. fragile X syndrome, tuberous 
sclerosis complex, and neurofibromatosis). These cases account only for 10% of 
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patients with an autistic phenotype, while the majority of idiopathic ASDs may be based 
on specific gene regions which may be suggestive of an ASD. (Klauck et al. 2006). 
 There are only a handful of loci which have been found to be present in a larger 
population of Autism patients. The more prevalent ones are 16p11.2 which has only 
been found in 1% of cases (Weiss et al. 2008), maternal Duplication of 15q11 
(Depienne, et al. 2009), and more recently 5p14.1 (Wang et al. 2009). The majority of 
the genetic associations involved with autism are found to be de novo variants or 
random mutation which occurs in the germ line DNA. Rare de novo copy number 
variants have been implicated in 7% of families with ASDs, but only in 1% of control 
families (Sebat et al. 2007). Due to the prevalence of CNVs found in Autism it is our 
main goal to conduct whole-genome screens of autistic patients to define regions with 
acknowledged susceptibility genes for autism for further fine mapping by association 
studies and to verify de novo or inherited variants. As previously stated, CNVs are a 
prevalent structural variation which has been implicated in many disorders by various 
studies. Presently there has been a large volume of research dedicated to 
understanding the pathophysiology of autism and other neurological and psychiatric 
conditions. To supplement this data, we are conducting CNV discovery to find novel and 
de novo variations in autistic patients.   
Due to the commonness of this disorder there are reasons to suspect that 
common variation will be found to play a large role in the etiology of ASDs. Within the 
normal human genome, most of the variation in a given population is accounted for by 
polymorphisms that are present in more than 1% of individuals. These, by definition, are 
considered common alleles. It would be logical then to hypothesize that a disease that 
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is common would reflect this overall architecture. This would hold true as long as natural 
selection against these alleles did not play a significant role (Gupta et al. 2006). 
Methods and Materials 
DNA samples 
Reference and sample genomic DNA samples were gathered under human 
studies protocol IRB06-00414 (Carlos Alvarez, Nationwide Children’s Hospital). The 
reference DNA was from a normal individual who has no known disease or genetic 
abnormality. The blood samples were collected from autistic children and their parents, 
and provided to us by the Central Ohio Registry for Autism (CORA, which has its own 
IRB protocol), which was created by and continues to be headed by Dr. Gail Herman 
(Nationwide Children’s Hospital). Blood was processed into purified DNA, and live 
lymphocyte B cells from the latter were EBV-immortalized (Epstein - Barr virus) and 
multiple aliquots were frozen in N2 (liq). DNA was then extracted and purified from those 
cell lines to be used in our study. 
The children involved in our study were clinically evaluated and diagnosed with 
autism (CORA). All these autistic children were negative for large genomic alterations 
using clinical cytogenetics (but had not been analyzed for submicroscopic alterations by 
aCGH (CORA)). All autistic children in this study are male, ranging from ages 4-18, and 
nine are of European ancestry and one individual is of African (Cameroon) ancestry. 
DNA purity was determined by UV spectrophotometry (Nanodrop 1000). 
260/280nm Absorbance ratios >1.8, and 260/230nm Absorbance ratios >2.0 were 
considered high quality. In addition DNA was analyzed by agarose gel electrophoresis 
to ensure that the DNA was of high molecular weight.  
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DNA labeling and array hybridization 
  Once the quality control on the DNA was complete 400ng of sample and 
reference DNA were labeled with Cyanine 3–dCTP and Cyanine 5–dCTP, respectively 
(Cy3/Cy5, Perkin Elmer Life Sciences). Klenow, enzyme, and a random octomer primer 
(Operon) were used in the random priming reaction. The enzyme reactions were 
incubated in the dark at 37°C for approximately 18 hours. DNA samples were purified 
from unincorporated label using spin columns (Microcon YM-30, Millipore). Purified 
samples were mixed with 100 µL of human Cot-1 DNA (purified highly repetitive-
sequence DNA (Invitrogen)), which was used to block repetitive sequence. DNA was 
resuspended in 45 µl of DIG Easy hybridization solution (Roche). Quality control of DNA 
labeling was conducted by measuring dye incorporations (Nanodrop 1000). A threshold 
of 8pmol/µL was used to determine acceptable dye incorporations. The sample mixture 
was denatured at 85°C for 10 min., and repetitive sequences were blocked by 
hybridization at 45°C for 1 hour. The mixture was applied onto SMRT BAC arrays 
containing 26,363 clones spotted in duplicate on single slides (manufactured in the lab 
of Dr. Wan Lam, BCCRC, Vancouver; Wong et al. 2006). [The clones were selected 
from the SMRT clone set, to optimize tiling coverage of the genome; the clone list is 
available at the SMRT Array Web site (Ishkanian et al. 2004).]  A cover slip was added 
(Fisher Scientific), and the slide was placed in a hybridization chamber along with 15µl 
of water for approximately 36 hours. Cover slips were then removed and arrays were 
washed three times for 5 min each with agitation in 0.1% saline sodium citrate (SSC) 
and 0.1X SDS at 45°C. Arrays were rinsed three times for 5 min each in 0.1X SSC at 
room temperature and were dried by being placed in 50mL (Falcon) tubes and 
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centrifuged at 700g for 3 min. Once completely dry the arrays were scanned on a 
Genepix 4100 scanner which individually scans at Cy3 and Cy5 optimal wavelengths of 
595 and 685, respectively. 
Visual inspection of the scans were first used to detect major problems, such as 
printing errors due to manufacturing defects, and large regions of noise. The 
fluorescence intensities at 595 and 685 nm were used for the quality control, 
normalization, and processing of the data. The data was exported to an Excel file where 
the stringent criteria were applied for CNV discovery. Using the same BAC array 
platform, and the same criteria, Wong et al. (2006) experimentally determined the false 
positive detection rate to be 54.7%. The main CNV calling criteria were the standard 
deviation (SD) and signal to noise ratios (SNR) of individual BACs, and the log2 spot 
ratio showing a difference between the DNA quantity in the subject and the reference. 
SeeGH-Norm software was used to individually normalize array-wide signal intensities. 
SeeGH software (Chi et al. 2004) was used to visualize all high confidence BACs on the 
human genome assembly (Mar. 2006 (hg18), a.k.a. NCBI Build 36.1). Once all CNVs 
were visualized, certain thresholds were used to focus our findings. High quality probe 
signals were determined using a (SNR) of 10 for our very high confidence calls denoted 
as Tier 1 CNVs and a lower stringency of an SNR ratio of 3 for a lower confidence 
denoted as Tier 2 CNVs. This filtered data was then exported again on to an Excel file 
where a standard deviation of the autosomal data was found for each CNV. Spots which 
had no duplicate were removed, and any BACs that had been found previously in 4% or 
more of normals by Wong et al. (2006) were removed from our data. That study 
examined 95 normal individuals and found a large number of CNVs that occur naturally 
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in the population. Notably, that study and ours were both biased for Western 
Europeans.  Most importantly, the individuals from that study were used as our negative 
controls since that platform was identical to ours. The cut-off used by our lab to 
determine a called CNV was a standard deviation of -3.33 and 3.33. A loss would be 
called if the standard deviation of a BAC was -3.33 or less, and a gain would be called if 
the standard deviation of a BAC was 3.33 or more. The thresholds, quality control 
process, and the past expertise and guidance was provided by the Wan Lam lab (who 
created the platform and analysis tools).  
Results 
Array CGH was used to conduct CNV discovery in germ line DNA from 10 
children with autism, and presently, in the parents of one of the children. DNA copy 
number of each sample was quantified by comparative hybridization with a single 
normal reference DNA. The array platform used was the SMRT BAC array, which has 
tiling resolution representation of the human genome at 1.5-fold coverage (Wan Lam, 
BCCRC, Vancouver). The false positive detection rate must be considered during CNV 
discovery. The CNVs found in the study are not only to be accurate if validation is 
confirmed. In addition, as reported in the Wong et al. paper, the false positive and 
negative detection rate were 54.7% and 45.3% respectively (Wong et al. 2006). 
 As a control population, we used SMRT BAC array data generated under the 
same conditions from 95 normal individuals (Wong et al. 2006). Both that study and 
ours were biased for Western European ancestry (and both also included individuals of 
African ancestry).  Candidate CNVs were further analyzed by the use of the genome 
browser database at the University of California, Santa Cruz. The BAC-spanning 
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genomic coordinates of each called CNV region were entered into the browser and 
various supplementary data was accessed. In this way, we annotated the gene content 
of CNVs. We also used this database to determine whether previous studies had 
identified CNVs that coincided or overlapped with ours. Additionally, we determined 
whether CNV regions have segmental duplications (or low copy repeats) in the vicinity.  
The data has been categorized to optimize the discovery of candidate autism 
associated CNVs. First CNVs were called based on the number of array elements 
altered, either being single or multiple BACs. In total, our study identified 805 high 
confidence single-BAC CNVs, and 390 lower confidence single BAC CNVs (Table 2.) 
Our study has an average of more than 80 CNVs per individual. A single-BAC CNV has 
only one array element which has been altered and therefore has a lower confidence 
than a multi-BAC CNV which has more than two altered BACs (Fig. 3). The total 
number of CNVs found in our study is lower than that of Wong et al. (2006), using the 
same platform. This is presumably due to aspects of DNA hybridization that could relate 
to DNA quality, (which affects probe labeling efficiency) or manual processing of array 
hybridizations. In addition, variability of lab conditions such as temperature, and levels 
of ozone (which degrade Cy5) may have also led to lower CNV calls. Due to the 
thresholds based on SD and SNR, we have kept similar standards as the Wong et al. 
paper and can therefore assume the same false-positive percentage.  
Second, we identified the CNVs that were the most likely to be associated with 
disease: i.e., did not overlap regions of common CNV in normal individuals, affected 
genes previously implicated in autism, or were de novo mutations in a child (i.e., were 
not inherited from a parent) (Appendices, Table A1). We have called more than 20 high 
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confidence candidate autism CNVs per individual (Table 3). Of these CNVs 13 are tier 1 
(SNR cutoff of 10; see above) multi-BAC, and 3 are tier 2 (SNR cutoff of 3) multi-BAC 
CNVs.  
Total Number of CNVs 
  
# of 
Single 
BACs 
# of 
Multi-
BACs 
average # of 
CNV per 
individual 
# of gains per 
individual 
# of losses 
per 
individual 
Tier 1 (SNR 10) 805 37 81 47 33 
Tier 2 (SNR 3) 390 9 39 22 17 
Table 2. Total number of CNVs found in our study. Tier 1 are higher confidence CNVs which have a 
signal to noise ratio of 10 or greater. Tier 2 are lower confidence CNVs which have a signal to noise ratio 
of 3 or greater. The tier number determines a higher quality hybridization of slides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Single-BAC candidate CNV called in our study. Sample 137 shows a single-BAC CNV 
spanning 110156709-110355803 on chromosome 9q31.3. The BAC shifted to the right as seen by red 
outline represents a gain. 
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The candidate CNVs were prioritized according to two criteria. First we identified 
the highest possible confidence CNVs. The highest confidence CNV calls are those that 
are spanned by multiple BACs because they are detected by multiple array elements 
instead of one. In addition, they span a larger region of the genome and are thus likely 
to include more genes. The more genes involved in a copy number alteration, the higher 
likelihood it will have a phenotypic effect. Included in these were 37 high confidence and 
9 lower confidence multi-BAC CNVs (Table 2). All of our high confidence multi-BAC 
CNVs follow our optimal thresholds of SD, correlating to being called a gain or loss, and 
SNR, correlating to their placement in the tier system.  
In order to find high interest candidate CNVs possibly associated with autism, we 
filtered out CNVs that were detected in 4% or more of 95 normal individuals by aCGH 
with the same BAC array platform we used (Wong et al. 2006). The biochemical/genetic 
pathways and biological significance of genes potentially affected by CNV were 
screened for relevance to autism and brain development (using PubMed to screen the 
database of biomedical literature, and the Google search engine to screen the entire 
internet for published information). All CNVs were annotated manually by use of the 
UCSC genomic browser database (http://genome.ucsc.edu/). An example of a multi-
BAC CNV has been visualized by SeeGH software, which allows us to compare the 
probes within and between individuals (Chi et al. 2004) (Fig. 4). The top 12 multi-BAC 
candidate autism CNVs are among the most promising in our study, for their CNV call 
confidence and for the large number of genes affected. (Appendices, Table A2).       
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Table 3. CNVs that are high confidence (based on standard deviation, signal to noise ratio) and high 
interest (not being present in more than 4% of normal individuals which was found in another study of 95 
normal individuals using the same platform (Wong et al. 2006)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Multi BAC CNV found in our study. Sample A75 shows a multi-BAC CNV gain on chromosome 
2p13.1 which is marked in red. Multi-BAC CNVs are particularly high confidence because they affect 
multiple probes and can be of higher clinical interest as they can affect more genes since they span a 
larger region of the genome. 
Candidate Autism CNVs 
  
# of 
Single 
BACs 
# of 
Multi-
BACs 
average # 
of CNV per 
individual 
# of gains 
per 
individual 
# of losses 
per 
individual 
Tier 1 (SNR 10) 231 13 23 18 5 
Tier 2 (SNR 3) 149 3 15 11 4 
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We have separated our results into three forms: (1) rare or novel candidate 
CNVs that have not been found in previous studies, (2) CNVs that have been found in 
our study as well as larger studies also looking for CNV associations with autism, and 
(3) de novo or non- inherited CNVs.  
Novel candidate autism CNVs have been found in our study.  These CNVs are 
very interesting because they have rarely or never been seen in normals or other 
autistic children. The called CNV on chromosome 12 is a curious candidate CNV (Fig. 
5). Sample A39 has a multi-BAC CNV gain in the 12q13 region, with three overlapping 
BACs shifted to the right. The CNV is not found in any other children and has not been 
found in other studies. In addition, the high SNR make this CNV very compelling. Many 
such high interest candidate CNVs are in non polymorphic regions and are not found in 
less than 4% of normals. The majority of these multi-BAC CNVs are found in gene rich 
regions, suggesting they are likely to have phenotypic effects (which may be associated 
with autism). 
More than 25% of the total CNVs that have been called in our study have been 
found in current Autism CNV literature as well as the Autism Chromosome 
Rearrangement Database (ACRD). ACRD is an online database that has compiled the 
majority of autism CNVs from published studies such as C. R. Marshall et al. 2008, L. 
Sebat et al.2007, and Christian et al. 2008. Specifically, 64/231 of tier 1 CNVs and 
30/149 of tier 2 CNVs have been seen in other studies.  
Due to the possibility that some CNVs may be common in normal individuals, but 
be present at higher rates (that are statistically significant) in autistic individuals, we also 
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created our own database of all CNVs previously implicated in published studies 
(studies were identified by PubMed searching, and the data was manually 
  compiled and curated by myself and my advisor, Dr. Alvarez) (Appendices Table A3.) 
 
 Figure 5. Close up of chr12q aCGH analysis representing the 10 children who took part in this study. 
The middle panel, sample A39 has a large multi-BAC CNV that is seen by its deviation from the midline to 
the right. This shows a gain in copy number in this gene region. In addition one can see that all of the 
other children have no deviation at the same loci.  
 
 We initiated additional analysis to understand the heritability of these autism 
associated gene regions. Currently we have conducted one triad study to identify de 
novo variants in an autistic individual. The triad A39, A40, and A41 represent the child, 
father, and mother respectively. By conducting aCGH analysis on the parents, 
similarities and difference between the parents and the child can be observed. As seen 
in (Fig. 6), neither the father nor mother has a significant shift from the midline for any of 
the BACs that are affected in the child. However, the child has a compelling and 
interesting multi-BAC CNV (i.e., affects several genes) in the same region. Some genes 
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that are found in this region are MTIF, MTM, MTF, MT3, BBS2, NUP93, MTE, MT1X, 
and MT1E. Most of these genes begin with “MT”; they are known as metallothionein 
genes. They are a cluster of genes involved with protection against metal toxicity, based 
on experimental findings (Egli et al. 2006). Of the others, BBS2 could be suggestive of 
autism because of the associated with Bardet-Biedl syndrome which has clinical 
presentation of renal dystrophy, and mental retardation. Since neither parent appears to 
have this CNV, we consider this to be a likely de novo variant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Possible de novo variant found in our study. From left to right, the first individual is the father, 
the second the mother, and the third the autistic child. The child has a multi-BAC CNV which is not found 
in either parent. This suggests this variant is a de novo mutation (i.e., not inherited from either parent). 
Conclusion and Discussion 
 Our aCGH analysis of 10 autistic children yielded interesting findings. Once 
validated in follow-up studies, these results are likely to add to the current knowledge 
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about autism genetics and pathophysiology. In addition to identifying novel or rare 
CNVs, we have also found alterations in regions previously implicated in autism,  and 
have identified multiple candidate de novo CNVs. Analyzing the genetic and 
biochemical pathways of the genes located  in the CNV regions will help us to 
understand their significance. Although these CNVs need to be confirmed by other 
methods, we have designed our study to only detect high confidence variants. Our 
experimental and data analysis methodologies were calibrated to that of the Wan Lam 
lab.  
 The aCGH platform we used here has BAC array elements that span 150-200kb. 
These can generally detect CNVs at least 50kb in size, and can detect a subset of 
CNVs as small as 10kb (Kidd et al. 2006).  We first focused on those high-confidence 
CNV calls which were spanned by multiple BACs.  Not only were these calls detected 
by more than one array element, they were physically larger, and therefore more likely 
to be associated with disease.  The more genes that are either duplicated or deleted, 
the higher the chance of phenotypic consequences (Table 4). 
A large number of our candidate CNVs have also been found in other studies 
(see ACRD (http://projects.tcag.ca/autism/); (Appendix, Table A3)). One of these was 
identified by Glessner et al. (2009) in 33/2195 autistic patients, but only in 7/2519 
normal healthy individuals (Fig. 7a). This CNV’s association with autism was determined 
to have a P value of 3.57 x 10-6 and an odds ratio of 5.547. These values show the 
statistical significance of this CNV.  As seen in Fig. 7b, the Glessner CNV clearly 
overlaps a region we identified in our sample A26. Another interesting aspect of this 
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CNV is the fact that it is upstream of the AK123120 gene that is expressed in the brain 
and thus consistent with a possible role in autism. 
 
Figure 7a. A CNV identified by Glessner et al. (2009). The blue lines at the top indicate the SNP and 
copy number probe coverage. The green bars represent the BACs which span the CNV region of interest. 
The average breakpoint of the BAC is 13100000-13190000. This overlaps very well with a candidate CNV 
found in our study. This is an example of a CNV which has been called in our study along with larger 
studies involved with CNV discovery (Glessner et al. 2009). 
Figure 7b. The corresponding CNV to figure 7a. As one can see the blue line represents the CNV 
regions found in our study. The green line represents the CNV region found in the Glessner, Nature 
study. The close overlap shows a very compelling find. Since we have a CNV which corresponds to 
another published by another study examining over 1000 patients while our sample pool is only 10, our 
findings are very current and relevant. 
In our study we have identified variations affecting many interesting genes that 
may be associated with the phenotypic expression of autism. One such gene, present in 
Page | 33 
 
a high-confidence CNV region, is FOXP4. FOXP4 is a member of the forkhead box 
family of transcription factors which are involved with development of the brain and 
other organs. FOXP2, which is known to be co-expressed with FOXP4, has been 
implicated in the development of language skills, indicating this CNV has a possible role 
in the characteristic traits of autism (Katoh et al. 2004). Additional analysis is being done 
to find the genetic significance of the large number of other genes that have been found 
in CNV regions.  
In our study we have found nearly 80 high-interest CNVs in 10 autistic children, 
and more than 20 high-confidence candidate autism CNVs have been called per 
individual. This number is much higher than the majority of published studies of autism 
CNV discovery. For example, the recent Glessner et al. (2009) article in Nature, found 
15.5 CNV calls per individual. Our increased CNV call rate is due to the SMRT BAC 
array platform, which includes non-unique sequences –mainly those in regions of 
segmental duplications (or low copy repeats) –that have a 10-fold elevated rate of CNV. 
On the other hand, such non-unique sequences are not covered by oligonucleotide 
platforms because they cannot be uniquely mapped.  Although the false negative rate of 
the platform used in our study is quite high, we still have found a large number of high-
interest CNVs which may have been missed in others, but only a portion of those may 
actually be associated with autism. 
The next steps are to finish the triad analysis on families which have interesting 
candidate CNVs present in the child, and then validate the findings to ensure they are 
true calls and that their breakpoints are also accurate.  The validation will be done by 
fluorescence in situ hybridization (FISH), southern blotting, and Real Time PCR, all of 
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which give vital information that will enhance the findings so further examination can be 
conducted.    
The use of the SMRT array platform has greatly increased the quantity (due to its 
ability to find a larger number of CNVs) and quality (by providing higher-confidence 
calls) of CNVs discovered using aCGH techniques. This robust and versatile platform 
has clear advantages over techniques used in other recent studies, including higher 
signal-to-noise ratios and better standard deviations than other platforms, and it 
requires no sample amplification or the complexity reduction that is necessary for the 
SNP array approach to CNV discovery.  This study has supplied extensive data that will 
continue to be analyzed, validated, and annotated for autism relevance. We recommend 
the continued study of genome-wide analysis of structural variations, especially CNVs, 
to examine their role in ASD susceptibility, expression, and inheritability. This 
information can lead to clinical diagnostic testing to verify the origins of the disorder, and 
to the development of various therapeutic techniques to improve the lives of autistic 
individuals.  
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Unique ID Clone_Name
Chr 
No. Banding
BP StartPos 
(UCSC Mar 
2006)
BP EndPos 
(UCSC Mar 
2006)
Ratio 
(Normalize
d Cy3/Cy5 
Log2 Ratio) 
Standard 
Deviation
SNR 
Ch1 
(595)
SNR 
Ch2 
(685)
SDauto 
(standard 
diviation 
of the 
ratios of 
each 
probe 
from chr 1-
22)
Thresh 
Score 
(Ratio/SD
auto)
Sample 
(1 color / 
sample) g/l
RO32D18 RP11-465B22 1 p36.33 918163 1046699 0.239257 0.0398179 22.04 23.88 0.066748 3.584482 A26 gain
RO67D03 RP13-586E24 1 p36.32 2445100 2529860 0.269604 0.0375785 60.421 63.822 0.066748 4.039132 A26 gain
RO66F20 RP11-777P8 1 p36.13 16665329 16836250 0.3183 0.0291823 36.824 43.006 0.074813 4.254608 A8 gain
RO39F09 RP11-595I7 1 p36.11 24652247 24859224 0.299005 0.0381159 43.927 13.077 0.07167 4.171969 A75 gain
RO70O09 RP11-110H4 1 p36.11 25942591 26096516 0.238638 0.0114926 85.662 74.498 0.066748 3.575208 A26 gain
RO1F09 RP11-5J9 1 p34.3 36957071 37139825 -0.228811 0.0294411 59.623 42.789 0.066748 -3.42798 A26 loss
RO1B07 RP11-4M3 1 p33 46796925 46970566 0.258205 0.0256199 19.803 18.91 0.073771 3.500088 A137 gain
RO3P15 RP11-25A21 1 p32.1, p31.3 60807944 60980338 0.366584 0.0346807 14.537 12.389 0.073771 4.969216 A137 gain
RO42G20 RP11-627A12 1 p22.3 87569368 87753216 0.308185 0.0672437 13.552 13.867 0.073771 4.17759 A137 gain
RO26I24 RP11-361I6 1 p21.1 106247329 106413175 0.299415 0.0282921 39.587 30.651 0.066748 4.485752 A26 gain
RO1B14 RP11-7G12 1 q24.1 164123488 164287973 -0.237668 0.0029055 95.886 70.237 0.066748 -3.56068 A26 loss
RO20O17 RP11-267L3 1 q24.2 167222860 167381584 0.601437 0.0510008 15.779 21.489 0.073771 8.152757 A137 gain
RO27O02 RP11-380B22 1 q25.3 179466161 179671444 0.260274 0.0398688 25.499 27.352 0.073771 3.528134 A137 gain
RO58H09 CTD-2003B3 1 q32.1 204676883 204837914 0.257326 0.0132901 84.669 88.308 0.066748 3.855187 A26 gain
RO41A14 RP11-615M18 1 q32.2 205195912 205363199 0.488515 0.053383 13.854 15.353 0.073771 6.622047 A137 gain
RO50C17 RP11-718L9 1 q32.2 206299430 206471975 0.264449 0.0026008 15.212 12.054 0.073771 3.584728 A137 gain
RO17C23 RP11-196C8 2 p24.3 13032063 13188099 -0.238977 0.0139788 35.189 24.526 0.066748 -3.58029 A26 loss
RO50K16 RP11-723F23 2 p24.3 14978618 15161195 0.549819 0.0610438 12.692 16.756 0.073771 7.453051 A137 gain
RO36A02 RP11-526C24 2 p24.2 17558392 17595292 -0.257904 0.0307542 90.253 76.256 0.07167 -3.59849 A75 loss
RO34C02 RP11-482J4 2 p13.3 70684434 70893187 0.250953 0.0482021 18.036 20.897 0.073771 3.401784 A137 gain
RO2J19 RP11-15G4 2 p13.1 74988527 75142707 0.247251 0.0305937 50.426 54.109 0.07167 3.449853 A75 gain
RO12O17 RP11-124P5 2 p13.1 75115704 75274189 0.448689 0.0254438 22.177 19.261 0.07167 6.260486 A75 gain
RO50K22 RP11-723H1 2 p13.1 75226841 75425458 0.242051 0.0018498 38.945 46.245 0.07167 3.377299 A75 gain
RO6A04 RP11-58E9 2 p11.1 91654153 91685783 0.351565 5.23E-05 24.3 23.879 0.066748 5.267049 A26 gain
RO17I12 RP11-203K11 2 q11.1 95399978 95568811 0.464566 0.0002383 86.516 162.83 0.111086 4.182039 A39 gain
RO42O15 RP11-625O3 2 q11.2 95857272 96031199 -0.341205 0.0293874 16.539 16.305 0.100303 -3.40174 A51 loss
RO66P11 RP11-763O1 2 q11.2 96212625 96383203 0.350505 0.0059807 20.845 36.255 0.100303 3.494462 A51 gain
RO21H08 RP11-297B14 2 q13 113143567 113352583 0.279864 0.0194546 65.921 56.978 0.07167 3.904897 A75 gain
RO8C07 RP11-78E20 2 q14.2 121240000 121441961 -0.407064 0.0161383 64.844 99.175 0.111086 -3.6644 A39 loss
RO49H24 RP11-716M19 2 q14.2 121375188 121577515 0.403387 0.0208024 12.494 19.77 0.100303 4.021684 A51 gain
RO40E07 RP11-601F13 2 q22.1 138230775 138373820 -0.236377 0.0555022 14.119 12.67 0.06782 -3.48536 A118 loss
RO25K12 RP11-350N1 2 q22.1 140265043 140466338 0.321984 0.0300033 10.648 13.873 0.06782 4.747626 A118 gain
RO17I14 RP11-203K19 2 q31.1 176631931 176808639 0.298515 0.0255287 79.566 82.436 0.066748 4.472269 A26 gain
RO70O11 RP11-111C16 2 q31.1 177083977 177242722 0.292749 0.0007078 75.093 72.711 0.066748 4.385884 A26 gain
RO53G22 RP11-758O1 2 q31.1 177427021 177609208 0.273342 0.0136663 10.393 12.304 0.073771 3.705277 A137 gain
Tier 1
Appendix 1: Table A1. All Tier 1 and Tier 2 Candidate Autism CNVs  
 
 
 
 
 
 
 
 
 
 
RO51C09 RP11-730M4 2 q31.3 180961085 181117649 0.296393 0.01393 15.189 16.221 0.073771 4.017744 A137 gain
RO25J10 RP11-355N23 2 q33.3 206900670 206969163 0.294401 0.0017416 64.761 56.097 0.066748 4.410634 A26 gain
RO40L08 RP11-611J23 2 q33.3, q34 208953051 209141331 0.319108 0.0113696 74.004 62.374 0.07167 4.452463 A75 gain
RO9N22 RP11-101G6 2 q36.1 221890614 222065341 -0.30663 0.0035702 18.414 12.658 0.066748 -4.59385 A26 loss
RO21D08 RP11-296C11 2 q36.2 225777102 225943830 0.257383 0.0116644 37.426 40.444 0.07167 3.591224 A75 gain
RO14G12 RP11-154A7 2 q37.1 232092877 232245500 0.247784 0.0653572 19.718 12.273 0.07167 3.45729 A75 gain
RO35M15 RP11-502F10 3 p22.1 40168920 40336928 0.270671 0.0225228 11.526 11.995 0.073771 3.669071 A137 gain
RO51N14 RP11-740P15 3 q22.1 43042214 43198446 0.336884 0.0356339 19.905 26.035 0.06782 4.967325 A118 gain
RO36D08 RP11-542F6 3 q25.1 134415378 134606591 0.318403 0.0585909 62.978 54.105 0.07167 4.442626 A75 gain
RO62P23 RP11-117K20 3 q26.31 159315572 159494764 0.27218 0.0254855 85.082 62.139 0.07167 3.797684 A75 gain
RO33O01 RP11-468N7 3 q27.1 173085106 173277471 0.299726 0.0652653 10.254 10.187 0.073771 4.062924 A137 gain
RO42J08 RP11-631P4 3 q29 185337137 185502784 0.24442 0.0008252 39.746 43.632 0.07167 3.410353 A75 gain
RO47L16 RP11-694E12 3 q29 193655933 193832580 -0.454193 0.0028617 109.59 82.12 0.07167 -6.33728 A75 loss
RO60N17 CTD-2235O1 3 q29 195414663 195511908 0.291416 0.042198 10.555 11.129 0.06782 4.296904 A118 gain
RO70O08 RP11-141L5 4 p16.3 819328 983918 0.32789 0.0011929 20.856 21.556 0.066748 4.912357 A26 gain
RO37F18 RP11-565M6 4 p16.3 1530742 1691087 0.222639 0.0349339 26.53 22.752 0.066748 3.335516 A26 gain
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RO31O14 RP11-448F22 4 p16.3 2384072 2472983 0.332472 0.006866 23.859 26.812 0.073771 4.506812 A137 gain
RO31O13 RP11-444J4 4 p16.3 2475663 2659104 0.337627 0.0021786 19.321 25.107 0.073771 4.57669 A137 gain
RO30K14 RP11-431J16 4 p15.31 21912514 22118512 0.382154 0.042181 10.916 13.891 0.073771 5.180274 A137 gain
RO31P08 RP11-453M22 4 p14 37206944 37369549 0.283444 0.0598149 60.75 65.942 0.07167 3.954849 A75 gain
RO41N01 RP11-620D19 4 p11 48760365 48941412 -0.2838 0.0269542 127.71 87.773 0.066748 -4.25181 A26 loss
RO23K06 RP11-322A9 4 p11 48855123 48941378 -0.23954 0.0124458 102.81 77.167 0.066748 -3.58872 A26 loss
RO17B09 RP11-205G17 4 p11 49184918 49238843 -0.434054 0.0352295 38.012 11.879 0.112428 -3.86073 A1 loss
RO51E09 RP11-730P6 4 p11 49281935 49326349 -0.226318 0.0030547 128.64 87.012 0.066748 -3.39063 A26 loss
RO70L16 RP11-186C5 4 q13.3 75475766 75637578 -0.239452 0.0108392 45.775 43.097 0.07167 -3.34104 A75 loss
RO68K09 RP11-18O22 4 q26 117414505 117570802 0.240949 0.0089449 70.636 68.062 0.066748 3.609831 A26 gain
RO27A12 RP11-375P10 4 q31.1 139960018 140140654 0.263714 0.0176508 56.051 59.119 0.066748 3.95089 A26 gain
RO4L03 RP11-37E18 4 q32.1 157999304 158162935 0.405522 0.0132561 13.9 13.703 0.073771 5.497038 A137 gain
RO45F04 RP11-663K16 4 q32.3 168924247 169095790 -0.333067 0.0223474 24.956 26.757 0.06782 -4.91104 A118 loss
RO45A04 RP11-656C20 5 p15.33 350722 447421 0.251496 0.0173114 64.233 58.454 0.066748 3.767843 A26 gain
RO14N24 RP11-161F13 5 p15.33 1562894 1724268 -0.255112 0.0135842 18.612 14.805 0.06782 -3.7616 A118 loss
RO55C23 RP11-778E14 5 p15.33 2592645 2774473 0.289887 0.0625217 21.958 25.165 0.073771 3.929552 A137 gain
RO70L14 RP11-186B21 5 q13.2 69527543 69653811 -0.30141 0.0005827 117.98 93.54 0.07167 -4.20553 A75 loss
RO58O16 CTD-2001M9 5 q13.2 70661551 70764108 -0.331258 0.0281294 57.908 43.987 0.07167 -4.62199 A75 loss
RO70G21 RP11-96H22 5 q13.3 74959279 75127937 0.262196 0.0008365 47.373 39.849 0.066748 3.928148 A26 gain
RO65J17 RP11-594A24 5 q13.3 75109899 75295154 0.414459 0.0038848 12.21 13.135 0.073771 5.618183 A137 gain
RO69C14 RP11-20M13 5 q14.3 82908893 83054341 0.32423 0.0950719 10.952 10.522 0.06782 4.780743 A118 gain
RO40O18 RP11-606H14 5 q33.2 153245135 153421108 0.343733 0.0157204 21.997 29.774 0.073771 4.65946 A137 gain
RO58G19 RP11-812K10 6 p25.3 71610 284699 0.26557 0.0093798 58.101 55.975 0.066748 3.978696 A26 gain
RO66I01 RP11-664H18 6 p25.1 5710060 5886212 -0.246554 0.091728 129.51 87.015 0.066748 -3.6938 A26 loss
RO70O21 RP11-113F21 6 p22.1 29148090 29304253 0.286076 0.0039669 21.004 19.488 0.066748 4.285911 A26 gain
RO58D24 CTD-2007P10 6 p21.33 30972604 31085380 0.423626 0.0591509 53.84 95.403 0.111086 3.813496 A39 gain
RO12D20 RP11-135J9 6 p21.33 31440461 31606959 0.258084 0.0278176 29.574 34.486 0.073771 3.498448 A137 gain
RO10D07 RP11-107C8 6 p21.31 34540001 34703255 0.249976 0.0578555 19.305 12.838 0.073771 3.38854 A137 gain
RO43I01 RP11-634F13 6 p21.1 41456894 41671891 0.532961 0.091675 58.274 133.7 0.111086 4.797733 A39 gain
RO42C17 RP11-624F22 6 p21.1 41510587 41701770 0.431051 0.0025908 54.377 81.485 0.111086 3.880336 A39 gain
RO70I24 RP11-130K11 6 q14.3 86034664 86138958 -0.285843 0.0246773 13.995 11.292 0.06782 -4.21473 A118 loss
RO42O20 RP11-628G14 6 q15 87679748 87841029 0.399379 0.047176 27.246 34.081 0.073771 5.413767 A137 gain
RO50O10 RP11-723N6 6 q15 88886560 89038114 0.356687 0.0051315 13.218 19.318 0.073771 4.835057 A137 gain
RO40D08 RP11-610E23 6 q16.3 101611771 101775605 0.250149 0.0170286 67.66 52.704 0.07167 3.490289 A75 gain
RO64G13 RP11-346C16 6 q21 110941778 111130824 0.28682 0.0018873 11.036 13.805 0.073771 3.887978 A137 gain
RO61G21 CTD-2310D7 6 q22.1 113915311 114052447 -0.350276 0.0871679 14.866 11.191 0.06782 -5.16479 A118 loss
RO28L07 RP11-403C11 6 q22.1 114313227 114352792 -0.257576 0.0301249 83.226 69.687 0.066748 -3.85893 A26 loss
RO32K13 RP11-455L8 6 q23.2 131432645 131623624 0.358431 0.0160195 12.156 14.356 0.073771 4.858698 A137 gain
RO32K01 RP11-455I14 6 q25.2 155418033 155593336 0.262583 0.0910598 13.557 16.742 0.073771 3.559434 A137 gain
RO50J04 RP11-728F5 6 q27 170345513 170469123 0.262764 0.0238634 61.703 55.16 0.066748 3.936657 A26 gain
RO60F04 CTD-2260L17 7 p22.3 797562 898228 0.226066 0.0228289 42.207 43.148 0.066748 3.386858 A26 gain
RO31K13 RP11-442P13 7 p22.1 5007384 5179039 0.329093 0.0304544 23.405 28.441 0.073771 4.461008 A137 gain
RO61G10 CTD-2380A4 7 p21.2 15155609 15320915 0.242054 0.0106752 10.604 10.458 0.066748 3.626386 A26 gain
RO32K03 RP11-455J15 7 p21.1 16700151 16863920 0.318534 0.0127032 15.958 16.922 0.073771 4.317876 A137 gain
RO40E05 RP11-601F7 7 p15.3 24617413 24785003 0.271527 0.0003769 14.893 11.649 0.073771 3.680674 A137 gain
RO61O20 CTD-2010E11 7 p14.1 40782944 40818119 0.242927 0.0239009 39.819 40.455 0.066748 3.639465 A26 gain  
 
 
 
 
 
 
 
 
 
 
 
 
RO36D20 RP11-542I1 7 p11.2 56616401 56796200 0.365986 0.0423444 95.806 72.534 0.07167 5.106544 A75 gain
RO63N18 RP11-325K1 7 q11.21 66036595 66209226 0.522774 0.0812204 12.339 14.063 0.073771 7.086443 A137 gain
RO35L04 RP11-519I5 7 q11.22 71722139 71877344 -0.2311 0.0976005 15.116 14.405 0.06782 -3.40755 A118 loss
RO68N06 RP11-818I12 7 q31.33 124755570 124943364 0.28215 0.0416231 17.913 17.156 0.066748 4.227093 A26 gain
RO22J13 RP11-313O20 7 q34 140553376 140720323 0.255915 0.0944334 14.379 18.6 0.073771 3.469046 A137 gain
RO13F09 RP11-143G2 7 q34 141730127 141884603 0.265932 0.0333132 29.643 34.038 0.074813 3.554623 A8 gain
RO52H15 RP11-749O22 7 q36.1 148697310 148888695 0.306651 0.0160294 52.567 50.532 0.066748 4.59416 A26 gain
RO30O05 RP11-428M3 7 q36.1 150572713 150800286 0.228269 0.0197092 45.52 44.686 0.066748 3.419863 A26 gain
RO3L16 RP11-26I6 7 q36.2 152632106 152791685 0.281292 0.0641551 12.535 16.133 0.073771 3.813043 A137 gain
RO59B10 CTD-2041J20 7 q36.3 157396437 157519058 0.26356 0.0291922 17.256 19.154 0.074813 3.522917 A8 gain
RO52G07 RP11-744K13 7 q36.3 157760321 157945126 0.49325 0.0090227 29.363 62.037 0.111086 4.440253 A39 gain
RO44L08 RP11-652N4 8 p23.2 4901876 5127620 0.240296 0.0615756 74.877 55.144 0.07167 3.352811 A75 gain
RO42A02 RP11-625P23 8 q12.1 58003559 58174053 0.249751 0.0119968 14.929 13.913 0.073771 3.38549 A137 gain
RO6J22 RP11-65D13 8 q21.11 77643686 77816008 0.269201 0.0592499 12.038 10.021 0.07167 3.756118 A75 gain
RO59H22 CTD-2085I3 8 q22.1 94655709 94761228 0.224219 0.0118865 96.433 104.99 0.066748 3.359187 A26 gain
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RO50K04 RP11-723E18 8 q24.13 126155750 126356347 0.561082 0.0029083 13.207 17.029 0.073771 7.605726 A137 gain
RO35J04 RP11-518L1 8 q24.3 144584483 144718307 0.245826 0.0073539 15.161 16 0.066748 3.682897 A26 gain
RO57J07 RP11-806N14 9 p22.2 18221982 18449492 0.272444 0.0374392 25.771 25.428 0.07167 3.801367 A75 gain
RO41D22 RP11-621D23 9 p13.3 35715248 35951025 0.44273 0.0636283 87.364 194.47 0.111086 3.985471 A39 gain
RO22M24 RP11-312A20 9 p13.3 35825343 36043213 0.232816 0.0090786 53.073 54.533 0.066748 3.487985 A26 gain
RO26P18 RP11-370J5 9 p13.1 39073855 39224644 -0.244675 0.0318827 59.581 51.682 0.07167 -3.41391 A75 loss
RO17M12 RP11-204I2 9 p11.2 43583843 43746434 -0.255637 0.0269047 17.831 14.053 0.07167 -3.56686 A75 loss
RO8H01 RP11-88D3 9 q12 66405147 66476865 0.251042 0.0954679 35.263 40.091 0.073771 3.40299 A137 gain
RO23I05 RP11-318L1 9 q12 68164115 68282615 -0.387626 0.0059263 16.026 14.248 0.112428 -3.44777 A1 loss
RO8D23 RP11-87H9 9 q12 68221319 68447264 -0.376495 0.0375693 32.902 37.234 0.112428 -3.34877 A1 loss
RO59G20 CTD-2019O15 9 q21.32 84869245 85007158 0.363446 0.0463226 16.402 19.346 0.06782 5.35898 A118 gain
RO32C03 RP11-454G15 9 q31.3 110156709 110355803 0.678205 0.0187376 11.699 15.267 0.073771 9.193382 A137 gain
RO18E03 RP11-220D10 9 q31.3 110395342 110547877 0.350597 0.0375134 24.441 32.858 0.100303 3.495379 A51 gain
RO50K10 RP11-723F2 9 q31.3 111163247 111380118 0.310704 0.0454656 23.687 28.806 0.073771 4.211736 A137 gain
RO48C19 RP11-695L17 9 q34.3 138380703 138494631 0.222865 0.0281676 26.798 27.225 0.066748 3.338902 A26 gain
RO62H21 RP11-102I24 10 p13 13089369 13228260 0.251713 0.0154517 91.261 94.577 0.066748 3.771094 A26 gain
RO67J07 RP13-617N7 10 q11.1 42020851 42040383 0.223057 0.0110125 97.237 106.62 0.066748 3.341778 A26 gain
RO61K11 CTD-2318O3 10 q11.1 42020851 42040383 0.42606 0.0017692 127.98 314.81 0.111086 3.835407 A39 gain
RO58F11 RP11-818P1 10 q11.21 42987824 43202215 0.281415 0.0025307 10.327 11.606 0.074813 3.761579 A8 gain
RO4M13 RP11-30N1 10 q11.23 51121592 51195063 -0.289387 0.005939 17.055 13.701 0.06782 -4.26699 A118 loss
RO50C08 RP11-722F10 10 q23.1 84452403 84618004 0.251853 0.0120866 18.7 18.324 0.073771 3.413984 A137 gain
RO64F18 RP11-448I7 10 q26.3 134955684 135066765 0.247872 0.0041274 35.496 35.033 0.066748 3.713549 A26 gain
RO62A23 RP11-23J21 11 p15.4 3349519 3535987 -0.258074 0.0404571 59.242 41.311 0.07167 -3.60087 A75 loss
RO66P09 RP11-763N14 11 p15.1 16437283 16630905 0.261995 0.0106759 124.09 121.67 0.066748 3.925136 A26 gain
RO66P21 RP11-766K9 11 p14.3 23361050 23525759 0.262915 0.0372596 102.82 109.38 0.066748 3.93892 A26 gain
RO16P20 RP11-195I23 11 p11.2 44985558 45145067 0.298712 0.0206256 60.993 66.465 0.07167 4.167881 A75 gain
RO35H03 RP11-511O3 11 q12.2 59935908 59963112 -0.346224 0.0060762 122.3 96.389 0.066748 -5.18703 A26 loss
RO44E17 RP11-642F7 11 q13.1 65023037 65185629 0.270586 0.0029536 39.971 45.262 0.07167 3.775443 A75 gain
RO56C23 RP11-791I20 11 q13.4 74652389 74835071 0.263234 0.0774126 19.616 19.974 0.073771 3.568259 A137 gain
RO17P04 RP11-217K21 11 q13.5 76392326 76536143 0.247836 0.0317434 46.635 15.624 0.066748 3.71301 A26 gain
RO18B14 RP11-239K22 11 q21 95994439 96152262 0.290185 0.0924047 16.715 26.075 0.06782 4.278753 A118 gain
RO14C05 RP11-150H9 11 q23.3 118603789 118758082 0.230834 0.0169338 44.992 41.54 0.066748 3.458291 A26 gain
RO21F12 RP11-296M15 11 q25 133545363 133721889 0.271078 0.0195374 71.407 71.264 0.066748 4.061215 A26 gain
RO50N14 RP11-729M2 12 p13.33 2098197 2246866 0.307968 0.0250917 21.003 26.011 0.06782 4.540961 A118 gain
RO31K14 RP11-447J10 12 p13.31 5573581 5743850 0.312687 0.0919338 11.957 22.74 0.073771 4.238617 A137 gain
RO31C13 RP11-440N2 12 q12 36720939 36889175 0.405225 0.0549528 16.721 21.189 0.073771 5.493012 A137 gain
RO14P21 RP11-158I2 12 q13.13 52541438 52732799 0.458524 0.009104 79.974 128.2 0.111086 4.127649 A39 gain
RO32J03 RP11-462E2 12 q13.13 52695946 52866729 0.609011 0.0088091 114.9 273.57 0.111086 5.482338 A39 gain
RO27L23 RP11-383J7 12 q13.2 53041821 53231620 0.389835 0.0262153 79.703 103.39 0.111086 3.509308 A39 gain
RO3L04 RP11-26G8 12 q14.1 57636373 57812533 0.362373 0.0441885 18.937 20.302 0.073771 4.912133 A137 gain
RO4C09 RP11-27M6 12 q23.3 106831834 106997898 -0.32588 0.0318997 37.869 31.34 0.07167 -4.54695 A75 loss
RO1A21 RP11-1C11 12 q23.3 106899825 107062279 -0.332661 0.0360865 49.144 20.44 0.07167 -4.64157 A75 loss
RO60N16 CTD-2280A16 12 q24.13 112581835 112696534 0.316783 0.0179711 11.197 13.785 0.06782 4.670938 A118 gain
RO40L15 RP11-608N12 13 q12.13 25309664 25502697 0.404711 0.0517673 15.196 20.754 0.06782 5.967428 A118 gain
RO1B03 RP11-4K24 13 q14.11 41655648 41810459 0.308232 0.0097277 10.817 12.028 0.073771 4.178227 A137 gain
RO32C14 RP11-457M18 13 q14.11 42325670 42471777 0.316926 0.0148054 13.269 15.378 0.073771 4.296078 A137 gain  
 
 
 
 
 
 
 
 
 
 
 
 
RO32K02 RP11-459A1 13 q22.2 74479268 74687974 0.357404 0.0224436 12.736 14.695 0.073771 4.844776 A137 gain
RO1I13 RP11-1M7 13 q22.2 75198429 75381103 0.535017 0.0674467 11.431 14.913 0.073771 7.252403 A137 gain
RO68D22 RP11-480F17 13 q22.3 76260854 76446840 0.312069 0.0027563 17.022 16.79 0.07167 4.354249 A75 gain
RO9P19 RP11-99I11 13 q34 112550821 112746773 0.284104 0.0371097 21.032 23.396 0.073771 3.851161 A137 gain
RO35N22 RP11-520H13 14 q23.3 64706822 64880159 0.264777 0.0223679 18.641 17.335 0.07167 3.694391 A75 gain
RO61E15 CTD-2305J20 14 q32.33 104788384 104893766 0.256025 0.0170491 33.843 38.265 0.07167 3.572276 A75 gain
RO67D17 RP13-594H12 14 q32.33 104822654 104944254 0.290204 0.0104206 46.644 49.238 0.066748 4.347756 A26 gain
RO40H07 RP11-607H20 15 q11.1 18273500 18473311 -0.251218 0.0055642 14.473 10.047 0.074813 -3.35795 A8 loss
RO44A01 RP11-641K15 15 q11.2 18781625 18946020 -0.248226 0.0027648 24.739 23.85 0.06782 -3.66007 A118 loss
RO28L19 RP11-403L7 15 q11.2 18898414 19048601 -0.385608 0.0093409 255.27 386.61 0.111086 -3.47126 A39 loss
RO37J13 RP11-561P13 15 q13.1 26135317 26310601 -0.245656 0.0483739 18.284 15.656 0.06782 -3.62218 A118 loss
RO61F22 RP11-6L23 15 q24.1 71985268 72141641 0.445803 0.0017855 27.509 52.143 0.111086 4.013134 A39 gain
RO54P21 RP11-775D1 15 q24.1 72244696 72412336 -0.379857 0.0284384 121.92 179.79 0.111086 -3.41949 A39 loss
RO34D17 RP11-486P18 16 p12.3 20442292 20598180 0.254507 0.0022627 26.95 31.016 0.06782 3.752684 A118 gain
RO42E14 RP11-626K17 16 p11.2 32287041 32440412 0.259538 0.0068257 115.8 119.75 0.066748 3.888326 A26 gain
RO1C23 RP11-1F10 16 q12.1 47811144 48013771 -0.233299 0.0091252 56.105 22.273 0.066748 -3.49522 A26 loss
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RO40K14 RP11-605N4 16 q13 55095980 55251063 0.388252 0.0066532 68.105 163.08 0.111086 3.495058 A39 gain
RO24J03 RP11-343H19 16 q13 55211316 55369561 0.584413 0.0157119 44.675 141.42 0.111086 5.260906 A39 gain
RO57F06 RP11-809H20 17 p11.2 17534762 17706303 0.313564 0.0009701 34.221 36.099 0.066748 4.697729 A26 gain
RO13D12 RP11-146G23 17 q11.2 28624283 28648111 -0.259572 0.0029571 96.169 66.917 0.066748 -3.88884 A26 loss
RO29J09 RP11-420B16 17 q21.32 43866044 44065387 0.24495 0.0301362 49.254 43.499 0.066748 3.669773 A26 gain
RO40C11 RP11-600O7 17 q21.32 44003179 44186865 0.452488 0.0085277 58.569 140.63 0.111086 4.073313 A39 gain
RO31G13 RP11-441O7 17 q23.3 58730625 58892053 0.306991 0.0270136 15.733 20.688 0.073771 4.161405 A137 gain
RO67A21 RP11-802F16 17 q25.3 73485102 73659590 -0.261082 0.0710048 23.332 14.339 0.074813 -3.48979 A8 loss
RO56D22 RP11-798C7 17 q25.3 76834696 77076142 0.248783 0.0440796 13.981 22.257 0.07167 3.471229 A75 gain
RO67I10 RP13-538H2 18 q11.2 19017248 19059585 0.239763 0.0025887 42.967 48.331 0.07167 3.345375 A75 gain
RO45A21 RP11-654B8 18 q21.1 42715677 42800239 0.50121 0.0158717 83.348 90.309 0.066748 7.508989 A26 gain
RO31P20 RP11-453P5 18 q21.32 56301614 56482301 0.244348 0.0560184 50.517 55.016 0.07167 3.409348 A75 gain
RO49C12 RP11-711F2 18 q23 71337342 71520536 0.238207 0.0453517 10.429 11.517 0.06782 3.512341 A118 gain
RO69E17 RP11-7H17 18 q23 75216360 75402240 0.256705 0.0354918 54.956 54.595 0.066748 3.845883 A26 gain
RO60F06 CTD-2260M22 19 p13.3 1377765 1490288 0.242766 0.0050084 26.584 32.1 0.07167 3.387275 A75 gain
RO67F13 RP13-600E22 19 p13.3 3408988 3533861 0.24949 0.0098373 66.675 79.588 0.07167 3.481094 A75 gain
RO5G04 RP11-46L10 19 p13.12 14015002 14153121 0.25763 0.0176784 42.295 45.186 0.07167 3.59467 A75 gain
RO44J16 RP11-652K21 19 p13.12 14069923 14245943 0.253994 0.0347055 49.545 44.306 0.07167 3.543937 A75 gain
RO36H08 RP11-543F7 19 q12 33742778 33936080 0.331168 0.0272844 81.343 58.754 0.07167 4.620734 A75 gain
RO10E12 RP11-104J24 19 q12 34942164 35091892 0.223538 0.0275906 32.664 11.699 0.066748 3.348984 A26 gain
RO44H08 RP11-652C23 19 q12 35155612 35336561 0.261465 0.0206779 74.085 58.742 0.07167 3.648179 A75 gain
RO61E06 CTD-2344L3 19 q13.32 50576103 50664187 0.225805 0.0038332 50.43 46.282 0.066748 3.382948 A26 gain
RO48B12 RP11-705C4 19 q13.42 60715146 60850444 0.241451 0.0253611 26.324 26.441 0.07167 3.368927 A75 gain
RO57M10 RP11-804M21 20 p13 1895714 2066809 -0.225321 0.0721362 83.454 56.92 0.066748 -3.3757 A26 loss
RO50D09 RP11-724J12 20 q11.21 30432283 30631518 0.230552 0.0162274 50.36 58.786 0.066748 3.454066 A26 gain
RO46G09 RP11-667G22 20 q11.22 31699917 31807042 0.234802 0.0086402 56.248 52.975 0.066748 3.517738 A26 gain
RO27A22 RP11-376B8 20 q11.22 33077333 33284163 -0.240186 0.0118327 17.418 13.416 0.06782 -3.54152 A118 loss
RO40L24 RP11-612A10 20 q11.22 33095140 33146318 0.266599 0.0203116 11.195 13.373 0.073771 3.613873 A137 gain
RO31O15 RP11-444K9 20 q13.13 47777796 47958064 0.448028 0.0844809 17.262 20.943 0.073771 6.073227 A137 gain
RO19D14 RP11-262B23 20 q13.2 53643329 53684580 0.239257 0.0042936 32.376 39.968 0.07167 3.338314 A75 gain
RO50C09 RP11-718I14 20 q13.33 60103776 60288903 0.224404 0.0118186 53.935 52.522 0.066748 3.361958 A26 gain
RO33J16 RP11-476I15 20 q13.33 62263781 62434320 0.26224 0.0019177 34.083 32.494 0.066748 3.928807 A26 gain
RO19F11 RP11-259G22 21 p11.1 10032184 10197104 -0.25157 0.0171311 96.007 72.421 0.07167 -3.51012 A75 loss
RO70F14 RP11-175M15 21 p11.1 10037729 10092616 0.246981 0.0129584 12.552 12.84 0.073771 3.347942 A137 gain
RO19P08 RP11-264C24 21 q21.1 17391475 17557175 0.250601 0.0384228 16.228 12.131 0.073771 3.397012 A137 gain
RO45B24 RP11-663E24 21 q21.3 28721529 28897123 -0.297887 0.0177427 22.795 19.221 0.06782 -4.39232 A118 loss
RO23D14 RP11-327M4 21 q22.3 44413607 44443805 0.261532 0.0176996 19.003 21.164 0.07167 3.649114 A75 gain
RO28K16 RP11-397E9 21 q22.3 44699015 44846952 0.447093 0.0508791 56.579 144.49 0.111086 4.024747 A39 gain
RO63G13 RP11-161A23 21 q22.3 45025735 45208462 0.237371 0.0313729 91.117 96.215 0.066748 3.556226 A26 gain
RO44H20 RP11-652F11 22 q21.1 18002150 18171498 0.291579 0.0207932 72.264 53.665 0.07167 4.068355 A75 gain
RO19B20 RP11-261O10 22 q21.2 24039097 24206958 0.260817 0.0099759 20.481 22.21 0.074813 3.486252 A8 gain
RO62B05 RP11-86H17 22 q21.3 28894288 29037473 0.259636 0.0290522 13.641 13.372 0.073771 3.519486 A137 gain
RO48P01 RP11-704C5 22 q22.13 37362475 37572224 0.262249 0.0248796 59.37 67.354 0.066748 3.928942 A26 gain
RO29J12 RP11-423E19 22 q22.3 49413876 49518700 0.241691 0.0292466 56.172 33.546 0.066748 3.620947 A26 gain
RO21H20 RP11-297F13 X p11.23 48575765 48734088 0.349604 0.0088735 52.794 65.633 0.07167 4.877968 A75 gain
RO17B08 RP11-211H10 X p11.23 49201123 49376616 -0.228992 0.0939533 17.517 14.119 0.06782 -3.37647 A118 loss  
 
 
 
 
 
 
 
 
 
 
 
 
RO32D20 RP11-465B24 X p11.21 56465528 56632629 0.259046 0.0620309 74.634 88.328 0.07167 3.614427 A75 gain
RO58D07 RP11-818I17 X p11.1 56752841 56935688 -0.446649 0.0071086 30.331 19.819 0.06782 -6.5858 A118 loss
RO18M04 RP11-231J22 X q22.3 105097484 105276081 -0.247856 0.0071793 32.716 25.318 0.07167 -3.45829 A75 loss
RO4A15 RP11-27E21 Y p11.2 6053399 6213222 0.586923 0.084705 91.583 220.15 0.111086 5.283501 A39 gain
RO53L12 RP11-764M21 Y p11.2 6507372 6664486 0.321714 0.0264861 62.714 66.877 0.066748 4.81983 A26 gain
RO65F22 RP11-622D24 Y p11.2 6516741 6719180 0.234058 0.0366642 36.348 29.581 0.066748 3.506592 A26 gain
RO19M18 RP11-258E22 Y p11.2 6540216 6691826 0.246632 0.0108286 70.828 69.215 0.066748 3.694972 A26 gain
RO10J07 RP11-108F14 Y p11.2 7755631 7921510 -0.250488 0.0038544 40.62 30.877 0.07167 -3.49502 A75 loss
RO27A16 RP11-375P13 Y p11.2 8465905 8635791 -0.287174 0.0194659 128.31 92.872 0.066748 -4.30236 A26 loss
RO31G02 RP11-446M21 Y q11.221 15089236 15303617 0.285442 0.0438328 10.655 11.804 0.073771 3.869298 A137 gain
RO1B21 RP11-5C5 Y q11.223 23920245 24077176 -0.292971 0.0138734 77.592 31.379 0.066748 -4.38921 A26 loss
RO34A05 RP11-478I22 1 p36.23 7959002 8148278 0.282164 0.0671978 8.309 8.653 0.076899 3.66928 A137 gain
RO68A24 RP11-84P16 1 p36.11 27205702 27404075 0.299351 0.0198414 7.62 5.099 0.076899 3.892781 A137 gain
RO68M09 RP11-561A23 1 p33 47992238 48169933 0.298906 0.0707262 9.241 9.201 0.071866 4.159213 A118 gain
RO9O23 RP11-94O18 1 p33 49280862 49433096 0.247428 0.0945091 3.008 3.503 0.071866 3.442908 A118 gain
Tier 2
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RO2M22 RP11-13M4 1 p31.3 63033731 63227884 -0.246048 0.0387297 4.549 3.099 0.071851 -3.42442 A75 loss
RO38H12 RP11-585M16 1 p31.1 74734998 74917065 0.504963 0.0274138 5.538 8.822 0.071866 7.026452 A118 gain
RO22N12 RP11-317F9 1 q23.1 156709465 156863209 0.274621 0.0775682 6.877 4.443 0.076899 3.571191 A137 gain
RO68M21 RP11-719L1 1 q31.3 193537539 193704669 0.430891 0.0171587 5.064 5.885 0.071866 5.995756 A118 gain
RO29B15 RP11-419B18 1 q31.3 195446765 195615132 0.269704 0.0397316 5.837 7.013 0.076899 3.50725 A137 gain
RO13G21 RP11-138M22 1 q42.13 228338069 228505163 0.52173 0.0348915 49.808 58.39 0.066893 7.799471 A26 gain
RO20J04 RP11-278O12 1 q42.3 232875925 233058172 0.259071 0.015055 5.784 4.822 0.076849 3.371169 A8 gain
RO68L18 RP11-488L18 1 q44 245339707 245542773 -0.267396 0.0339793 3.592 4.095 0.071866 -3.72076 A118 loss
RO61B09 CTD-2014D7 2 p16.1 57197583 57336716 0.370165 0.0298074 5.55 6.853 0.071866 5.150767 A118 gain
RO65N17 RP11-602P8 2 p12 75843805 76014895 0.390207 0.0110931 7.573 8.107 0.076899 5.074279 A137 gain
RO22D07 RP11-313B1 2 q21.1 130401477 130570107 0.539988 0.0963221 5.352 5.731 0.111152 4.858104 A39 gain
RO54G16 RP11-769N11 2 q21.1 130801038 130941683 0.379786 0.0721277 110.16 291.78 0.111152 3.416817 A39 gain
RO2J05 RP11-15D9 2 q22.1 139452943 139619513 -0.293557 0.0115449 6.298 4.227 0.076849 -3.81992 A8 loss
RO43C13 RP11-633H24 2 q24.1 154895951 155104293 0.252524 0.0343442 4.399 6.016 0.071866 3.513817 A118 gain
RO50I03 RP11-719O1 2 q24.3 165653881 165842181 0.27515 0.0594719 9.813 10.675 0.076899 3.57807 A137 gain
RO32K05 RP11-455J20 2 q32.2 190268101 190449901 0.315058 0.0092207 5.281 5.871 0.076899 4.097036 A137 gain
RO5E07 RP11-44A23 2 q34 212401435 212568601 -0.274036 0.0718385 11.777 6.499 0.076849 -3.5659 A8 loss
RO57F17 RP11-806C2 3 p26.3 1841954 2043596 0.240232 0.0079839 8.316 12.329 0.071866 3.342777 A118 gain
RO44C07 RP11-642A2 3 p24.3 21962388 22134044 0.422388 0.0169458 8.143 8.936 0.076899 5.492763 A137 gain
RO60I18 CTD-2185K4 3 p11.1 90525740 90584932 -0.24723 0.0648275 6.083 5.258 0.071866 -3.44015 A118 loss
RO43N10 RP11-641F4 3 q11.2 99591113 99756754 0.302473 0.0800014 6.077 5.741 0.071851 4.209726 A75 gain
RO3E02 RP11-20N7 3 q13.11 107633524 107818033 0.269103 0.0236845 8.401 8.459 0.076899 3.499434 A137 gain
RO65N05 RP11-599H1 3 q13.12 109384850 109586860 0.450016 0.0970822 8.18 8.958 0.076899 5.85204 A137 gain
RO68E12 RP11-539H11 3 q13.12 109435013 109636045 0.287275 0.0051343 6.524 4.181 0.076899 3.735744 A137 gain
RO50J03 RP11-725I19 3 q24 148478234 148676766 0.32309 0.0748734 6.35 8.755 0.071866 4.495728 A118 gain
RO27E10 RP11-378E6 3 q24 149152070 149322873 -0.260601 0.0161051 5.636 4.4 0.076849 -3.39108 A8 loss
RO66M20 RP11-718K10 3 q25.2 154255436 154412488 0.260832 0.0192821 6.535 7.868 0.076899 3.391878 A137 gain
RO45K17 RP11-655G22 3 q28 193133121 193305756 0.264123 0.0447648 16.052 8.214 0.076899 3.434674 A137 gain
RO59J10 CTD-2090B4 3 q29 194228217 194348803 0.906815 0.0213221 4.026 6.548 0.076899 11.79229 A137 gain
RO68A21 RP11-72I14 4 p16.3 2716373 2926405 0.412427 0.0956369 3.812 3.715 0.076899 5.36323 A137 gain
RO10B01 RP11-106H18 4 q13.3 72039825 72197229 -0.276666 0.0546742 5.111 5.205 0.071866 -3.84975 A118 loss
RO63N22 RP11-326O22 4 q13.3 72541949 72732136 0.393061 0.0421344 5.277 5.845 0.076899 5.111393 A137 gain
RO2B03 RP11-14A23 4 q21.23 86301196 86469048 0.355453 0.0407534 8.115 8.915 0.076899 4.622336 A137 gain
RO61H24 RP11-9H11 4 q26 115629364 115809774 0.364207 0.0365235 4.498 5.521 0.071866 5.067862 A118 gain
RO4I01 RP11-29M9 4 q28.3 134450123 134636219 -0.257497 0.0380494 8.058 6.269 0.076899 -3.34851 A137 loss
RO2D21 RP11-14K14 4 q35.2 190673393 190811644 0.398252 0.0870498 113.57 202.53 0.111152 3.582949 A39 gain
RO59C05 CTD-2011O21 4 q35.2 191039899 191138136 -0.371553 0.0119558 50.382 28.003 0.111027 -3.34651 A1 loss
RO9L14 RP11-101B14 5 q11.2 56361220 56544061 0.260312 0.0144271 9.004 12.895 0.076899 3.385116 A137 gain
RO2B04 RP11-15O24 5 q11.2 58487753 58646102 0.26282 0.0058421 5.667 5.776 0.076899 3.41773 A137 gain
RO66F05 RP11-734L8 5 q21.1 99194930 99380487 0.284348 0.0069671 8.292 8.876 0.076899 3.697681 A137 gain
RO59H12 CTD-2075G19 5 q21.2 103890873 104011391 0.319472 0.0169826 6.677 7.662 0.071866 4.445384 A118 gain
RO62P24 RP11-144H10 5 q23.1 120001738 120179752 0.405011 0.0413233 6.166 6.076 0.071866 5.635641 A118 gain
RO56F03 RP11-795P7 5 q23.2 123122540 123337265 0.434802 0.0284611 8.257 12.073 0.071866 6.050177 A118 gain
RO71D12 RP11-281H9 5 q23.3 128933631 129091165 0.443518 0.0229032 6.557 3.874 0.071866 6.171458 A118 gain
RO17P21 RP11-211F5 5 q33.1 149230059 149401295 0.230369 0.0210011 6.96 8.655 0.066893 3.443843 A26 gain
RO50J13 RP11-725K6 5 q33.2 152452352 152621841 0.336881 0.0315645 4.329 9.449 0.071866 4.687627 A118 gain  
 
 
 
 
 
 
 
 
 
 
 
 
RO66P24 RP11-798A10 5 q35.2 175185697 175351684 0.485902 0.0227787 11.089 5.603 0.071866 6.761222 A118 gain
RO35G22 RP11-506L4 5 q35.3 179650299 179831215 0.287939 0.0414556 10.536 9.282 0.071851 4.007446 A75 gain
RO42K13 RP11-625D22 6 p23 14164567 14370368 0.313224 0.0407591 8.809 11.924 0.071866 4.358445 A118 gain
RO66C01 RP11-650L9 6 p11.1 58483534 58667977 0.31482 0.0857721 5.217 8.314 0.076899 4.093941 A137 gain
RO9A13 RP11-92I12 6 q16.3 103442960 103604028 -0.242568 0.0182229 4.97 4.239 0.071866 -3.37528 A118 loss
RO20F08 RP11-278D12 6 q22.1 113973438 114122489 -0.453926 0.0664879 12.549 8.891 0.071866 -6.31628 A118 loss
RO63N10 RP11-324H19 6 q22.31 125778192 125951756 0.36266 0.0680322 4.833 4.766 0.076899 4.716056 A137 gain
RO42F09 RP11-629G5 7 p21.1 18699485 18843722 0.272669 0.0120229 8.796 11.119 0.071866 3.794131 A118 gain
RO66F15 RP11-737K4 7 p14.1 38317139 38487572 0.270778 0.0836083 5.876 7.195 0.071866 3.767818 A118 gain
RO59D24 CTD-2057A11 7 p14.1 39094056 39250068 0.343873 0.0083736 7.782 9.9 0.071866 4.784919 A118 gain
RO63D12 RP11-299O9 7 q21.11 84194243 84365508 0.261287 0.0786911 5.634 4.704 0.071866 3.635753 A118 gain
RO67I21 RP11-1279M16 7 q21.13 88320492 88498710 0.46968 0.0461967 4.25 4.237 0.076899 6.107752 A137 gain
RO8D11 RP11-86H8 7 q31.1 110936386 111097114 -0.47501 0.0092985 16.874 9.816 0.071866 -6.60966 A118 loss
RO21I14 RP11-288L5 7 q32.3 130338884 130529807 -0.267959 0.0036932 9.555 5.364 0.076849 -3.48682 A8 loss
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RO32M12 RP11-459H7 7 q36.3 155707994 155932827 0.353235 0.0052071 22.606 7.246 0.076899 4.593493 A137 gain
RO67L21 RP13-631H19 8 p12 37399409 37535863 0.239449 0.0686205 16.19 9.359 0.071866 3.331882 A118 gain
RO64N10 RP11-465K16 8 p11.21 40778858 40972561 0.273926 0.0186655 8.474 5.456 0.071851 3.812417 A75 gain
RO44F10 RP11-651O22 8 p11.21 43028640 43224677 0.359587 0.0478506 4.669 3.746 0.071851 5.004621 A75 gain
RO40B22 RP11-610C11 8 q13.1 67209150 67436697 0.313038 0.0193316 5.438 3.974 0.071851 4.356766 A75 gain
RO58L24 CTD-2010C15 8 q21.11 77209526 77359732 0.444097 0.0590123 10.213 7.881 0.100216 4.431398 A51 gain
RO58N16 CTD-2010G21 8 q23.1 107583259 107713603 0.390155 0.009087 6.122 7.438 0.076899 5.073603 A137 gain
RO1A15 RP11-1A23 8 q24.13 124780127 124954329 -0.268898 0.0656775 8.283 6.38 0.076899 -3.49677 A137 loss
RO18P15 RP11-238O2 8 q24.22 132286383 132447254 0.29836 0.0102269 3.467 3.717 0.076899 3.879894 A137 gain
RO70B03 RP11-144K8 8 q24.3 142872355 143036068 0.501523 0.0945861 7.75 10.518 0.076899 6.52184 A137 gain
RO52N16 RP11-754E16 8 q24.3 143213865 143301529 0.41669 0.0497216 4.364 5.156 0.100216 4.157919 A51 gain
RO33G13 RP11-467K20 9 p21.3 21965732 22150198 0.444524 0.0467249 7.135 9.093 0.076899 5.780621 A137 gain
RO68F06 RP11-603E21 9 p21.1 29426014 29599173 0.331981 0.0067543 5.38 4.587 0.076899 4.317104 A137 gain
RO7F14 RP11-76C9 9 p21.1 31283693 31430872 -0.244388 0.0733835 5.46 4.681 0.071866 -3.40061 A118 loss
RO16D22 RP11-192I12 9 p13.3 35317928 35497319 0.666228 0.0970702 4.261 6.645 0.111152 5.993846 A39 gain
RO8N11 RP11-89I3 9 p12 40664093 40859472 -0.277965 0.0075816 16.648 8.281 0.076849 -3.61703 A8 loss
RO5I19 RP11-44K23 9 p11.2 43454734 43631985 -0.398667 0.0153272 8.137 5.699 0.076849 -5.18767 A8 loss
RO24P08 RP11-346L5 9 q12 68280728 68468579 -0.440136 0.0335968 5.995 10.256 0.131551 -3.34574 A14 loss
RO70F06 RP11-175G16 9 q22.1 89988405 90172770 0.24585 0.0199616 3.71 4.867 0.071866 3.42095 A118 gain
RO33C01 RP11-467B11 9 q31.1 101917303 102098845 0.28466 0.0549768 7.779 10.707 0.076899 3.701739 A137 gain
RO68A12 RP11-44G6 9 q31.2 107666667 107813656 0.303278 0.0027068 7.452 4.063 0.076899 3.943848 A137 gain
RO66D15 RP11-730A19 10 p13 13062307 13253628 -0.305214 0.007694 6.934 8.734 0.071866 -4.24699 A118 loss
RO60F20 CTD-2265D13 10 p11.22 31619726 31669689 -0.47732 0.0131501 6.411 8.046 0.131551 -3.6284 A14 loss
RO4I02 RP11-33I16 10 p11.22 31711322 31868133 -0.27203 0.0293789 14.3 7.336 0.076849 -3.5398 A8 loss
RO66H23 RP11-745A18 10 q11.23 53025431 53219133 0.247577 0.0688736 7.317 6.843 0.071866 3.444981 A118 gain
RO1I02 RP11-3D5 10 q21.1 57052410 57216834 -0.258206 0.0313411 5.922 3.949 0.076899 -3.35773 A137 loss
RO63J22 RP11-318J23 10 q21.3 65711959 65891133 0.583614 0.0814764 4.356 5.302 0.076899 7.589357 A137 gain
RO49F21 RP11-714J11 10 q23.33 95288778 95447597 0.24062 0.0474172 9.407 10.491 0.071866 3.348176 A118 gain
RO44G21 RP11-642K1 10 q26.13 125774542 125856402 0.313314 0.0276415 8.847 9.466 0.076899 4.074357 A137 gain
RO65D12 RP11-614E16 11 p14.1 27482159 27659272 0.325842 0.0414669 3.046 3.03 0.071866 4.534022 A118 gain
RO36C21 RP11-522B1 11 q13.4 74035539 74186161 0.266201 0.0328281 7.116 17.275 0.076899 3.461697 A137 gain
RO10B19 RP11-106P8 11 q14.1 79463518 79616021 -0.253873 0.0677924 6.739 6.443 0.071851 -3.53333 A75 loss
RO50J14 RP11-728G23 11 q14.1 84557237 84734682 0.337978 0.0340642 7.285 9.13 0.071866 4.702891 A118 gain
RO4E19 RP11-29E15 11 q14.1 84858148 85007763 -0.258203 0.0171912 11.884 6.614 0.076849 -3.35987 A8 loss
RO4A06 RP11-31E14 11 q22.3 106116314 106270764 -0.261308 0.05727 6.467 4.033 0.076849 -3.40028 A8 loss
RO10P15 RP11-109E10 11 q24.1 122629237 122798552 0.332965 0.0714934 4.373 3.928 0.076849 4.332717 A8 gain
RO50N15 RP11-726G1 12 p13.31 9478300 9654291 0.422425 0.0787759 8.693 12.036 0.071866 5.877953 A118 gain
RO6A15 RP11-55E6 12 p12.3 17693010 17816827 -0.292601 0.0250252 3.969 3.054 0.076899 -3.805 A137 loss
RO59N10 CTD-2103G15 12 q13.13 48916511 49097669 0.349693 0.0791161 7.767 8.691 0.076899 4.547432 A137 gain
RO18G23 RP11-222A15 12 q13.2 54118477 54287319 0.398468 0.0811836 5.489 4.834 0.071866 5.544597 A118 gain
RO69L10 RP11-78L11 12 q14.2 61570376 61745520 0.2413 0.0481929 20.234 5.343 0.071851 3.358339 A75 gain
RO9I16 RP11-96C17 12 q21.1 72035686 72183994 -0.312471 0.0349198 10.521 5.898 0.076849 -4.06604 A8 loss
RO68I21 CTD-2259B14 12 q21.1 72078504 72180449 0.302768 0.0510871 5.711 5.457 0.076899 3.937216 A137 gain
RO50L19 RP11-726C4 12 q21.32 85201787 85406009 0.312927 0.04517 5.227 6.116 0.076849 4.071972 A8 gain
RO13E22 RP11-140J20 12 q23.1 96283836 96447914 0.299916 0.0904121 4.876 4.411 0.076899 3.900129 A137 gain
RO69B04 RP11-63B18 12 q23.1 96437047 96592806 0.471741 0.0005402 40.47 72.191 0.111152 4.244107 A39 gain  
 
 
 
 
 
 
 
 
 
 
RO50I15 RP11-719P9 12 q23.1 99888331 100086721 0.392805 0.0268227 8.689 11.255 0.076899 5.108064 A137 gain
RO7M07 RP11-68I1 13 q13.2 34485139 34666538 -0.29899 0.0186556 7.648 4.721 0.076849 -3.89062 A8 loss
RO13E01 RP11-138D23 13 q21.32 66378445 66542967 -0.299936 0.0473627 4.869 3.511 0.076899 -3.90039 A137 loss
RO13N12 RP11-148O11 13 q21.32 67175227 67343618 0.303854 0.0822882 5.954 3.438 0.076899 3.951339 A137 gain
RO65L17 RP11-597C19 13 q21.33 67840459 68017187 -0.263205 0.0086522 7.072 4.626 0.076849 -3.42496 A8 loss
RO64B06 RP11-440M10 13 q31.1 82700870 82860135 0.688722 0.0846591 4.812 6.025 0.076899 8.956189 A137 gain
RO67G17 RP11-811J13 13 q32.1 96593476 96807474 -0.425103 0.0511132 7.924 6.5 0.071866 -5.91522 A118 loss
RO57F05 RP11-805P2 14 q12 26206655 26423170 0.252798 0.0313015 5.888 8.876 0.071866 3.51763 A118 gain
RO42G08 RP11-626P14 14 q12 26268979 26451739 0.497712 0.0497846 4.253 3.937 0.076899 6.472282 A137 gain
RO20O05 RP11-267E16 14 q13.1 33137499 33295974 0.850474 0.0564773 8.45 16.106 0.076899 11.05962 A137 gain
RO53F05 RP11-761B1 14 q21.1 39255957 39395014 0.246268 0.0361119 7.179 8.673 0.071866 3.426766 A118 gain
RO6D18 RP11-64F23 14 q21.2 41577260 41758651 0.240207 0.0055642 4.731 5.796 0.071866 3.342429 A118 gain
RO1A11 RP11-1A16 14 q21.3 45849446 46005115 -0.26412 0.0560403 11.353 9.676 0.076899 -3.43464 A137 loss
RO42O01 RP11-625K13 14 q23.1 58416882 58604908 0.269958 0.0615515 6.349 7.971 0.071866 3.756408 A118 gain
RO4A02 RP11-31E3 14 q24.3 73034707 73200904 -0.269286 0.0745114 8.889 6.07 0.076899 -3.50181 A137 loss
RO22O10 RP11-312F4 15 q21.3 54444378 54598110 0.658435 0.0623159 5.97 9.103 0.071866 9.161982 A118 gain
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RO5O21 RP11-45J10 15 q22.31 61579923 61736764 0.310979 0.0158349 12.833 8.957 0.066893 4.648902 A26 gain
RO29M16 RP11-418F16 15 q25.3 83235499 83414337 0.266466 0.0275984 15.926 7.079 0.076899 3.465143 A137 gain
RO1A24 RP11-2M20 16 p12.3 17074705 17250823 -0.267167 0.0743339 14.906 3.56 0.076899 -3.47426 A137 loss
RO32O01 RP11-456C20 17 q22 50530395 50751652 0.257666 0.0690553 9.363 11.737 0.076899 3.350707 A137 gain
RO69O17 RP11-17H21 17 q23.3 59684680 59845552 0.274758 0.0071057 10.52 9.025 0.076849 3.575297 A8 gain
RO70I09 RP11-98G11 17 q25.3 75393657 75565478 0.258249 0.030605 7.365 7.729 0.076899 3.358288 A137 gain
RO69N15 RP11-59I11 18 p11.32 37518 178873 0.906524 0.0297812 6.392 11.332 0.076899 11.7885 A137 gain
RO68A08 RP11-20I15 19 q13.33 57123599 57310836 0.27021 0.0255294 8.219 7.879 0.076899 3.51383 A137 gain
RO54P16 RP11-777H15 20 q11.21 30235601 30446679 0.476557 0.0044265 3.586 4.502 0.111027 4.292262 A1 gain
RO1J08 RP11-8J1 20 q13.13 48087051 48213089 -0.48188 0.0700382 14.208 13.568 0.131551 -3.66307 A14 loss
RO22F12 RP11-316F6 21 q21.2 25340087 25515908 0.288355 0.0839074 8.124 7.539 0.076899 3.749789 A137 gain
RO61I08 CTD-2385G3 21 q22.3 44518520 44620833 0.418591 0.0408149 3.547 3.976 0.076899 5.443387 A137 gain
RO68O02 RP13-513N1 X p21.3 27774072 27944947 0.276639 0.0693283 5.563 5.874 0.076849 3.599774 A8 gain
RO68B18 RP11-183D14 X p21.3 28368505 28540790 0.427304 0.0317378 7.309 6.696 0.076899 5.556691 A137 gain
RO61J17 CTD-2183E12 X p11.4 42299586 42425357 0.381155 0.0093833 8.247 8.666 0.076899 4.956566 A137 gain
RO67L07 RP13-626I16 X p11.21 56286352 56436154 -0.27009 0.0026177 4.906 3.875 0.071866 -3.75824 A118 loss
RO58H12 CTD-2008K20 X q21.32 92605050 92702456 0.327184 0.0500391 5.759 6.821 0.071866 4.552695 A118 gain
RO61P12 RP11-19M10 X q27.3 145275725 145451069 0.268799 0.0327518 4.392 4.661 0.071866 3.740281 A118 gain
RO15B01 RP11-166O18 Y q11.221 17496617 17617587 -0.262797 0.0397974 6.544 5.919 0.071866 -3.65676 A118 loss
RO1F03 RP11-5I7 Y q11.222 20889976 21063742 -0.313962 0.0168836 7 6.363 0.071866 -4.36871 A118 loss
RO58C02 RP11-814F19 Y q11.223 25156032 25333309 0.53047 0.0022069 6.159 14.612 0.131551 4.032428 A14 gain
RO29I22 RP11-418A1 Y q11.23 25546517 25733298 0.466481 0.0321437 3.275 4.214 0.131551 3.546009 A14 gain
RO50D01 RP11-724G24 Y q11.23 25678272 25845689 -0.37497 0.0400576 9.152 8.175 0.100216 -3.74162 A51 loss  
 
Legend   
         Sample 
ID   
         A1   
         A8   
         A14   
         A26   
         A39   
         A51   
         A75   
         A118   
         A137   
         
           Tier 1                   
 Thresh score (SD/SNR) <-3.33  or >3.33 
     
  
 SNR of BAC ≥10 
       
  
 Filtered out all CNVs present in >1 individual in 95 normals (same platform; Wan Lam)   
   
        
  
 Tier 2                   
 Thresh score  <-3.33  or >3.33 
     
  
 SNR of BAC ≥3 
       
  
 Filtered out all CNVs present in >1 individual in 95 normals (same platform; Wan Lam)   
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Chr 
No. Banding
BP StartPos 
(UCSC Mar 
2006)
BP EndPos 
(UCSC Mar 
2006)
Ratio 
(Normal
ized 
Cy3/Cy5 
Log2 
Ratio) 
Standard 
Deviation
SNR 
Ch1 
(595)
SNR 
Ch2 
(685)
SDauto 
(standard 
diviation 
of the 
ratios of 
each 
probe 
from chr 1-
22)
Thresh 
Score 
(Ratio/S
Dauto)
Sample 
(1 color 
/ 
sample) g/l
2 p13.1 74988527 75142707 0.2473 0.030594 50.426 54.109 0.07167 3.4499 A75 gain
2 p13.1 75115704 75274189 0.4487 0.025444 22.177 19.261 0.07167 6.2605 A75 gain
2 p13.1 75226841 75425458 0.2421 0.00185 38.945 46.245 0.07167 3.3773 A75 gain
2 q11.1 95399978 95568811 0.4646 0.000238 86.516 162.83 0.111086 4.182 A39 gain
2 q11.2 95857272 96031199 -0.3412 0.029387 16.539 16.305 0.100303 -3.402 A51 loss
2 q11.2 96212625 96383203 0.3505 0.005981 20.845 36.255 0.100303 3.4945 A51 gain
2 q31.1 176631931 176808639 0.2985 0.025529 79.566 82.436 0.066748 4.4723 A26 gain
2 q31.1 177083977 177242722 0.2927 0.000708 75.093 72.711 0.066748 4.3859 A26 gain
2 q31.1 177427021 177609208 0.2733 0.013666 10.393 12.304 0.073771 3.7053 A137 gain
4 p16.3 2384072 2472983 0.3325 0.006866 23.859 26.812 0.073771 4.5068 A137 gain
4 p16.3 2475663 2659104 0.3376 0.002179 19.321 25.107 0.073771 4.5767 A137 gain
4 p11 48760365 48941412 -0.2838 0.026954 127.71 87.773 0.066748 -4.252 A26 loss
4 p11 48855123 48941378 -0.2395 0.012446 102.81 77.167 0.066748 -3.589 A26 loss
4 p11 49184918 49238843 -0.4341 0.03523 38.012 11.879 0.112428 -3.861 A1 loss
4 p11 49281935 49326349 -0.2263 0.003055 128.64 87.012 0.066748 -3.391 A26 loss
6 p21.1 41456894 41671891 0.533 0.091675 58.274 133.7 0.111086 4.7977 A39 gain
6 p21.1 41510587 41701770 0.4311 0.002591 54.377 81.485 0.111086 3.8803 A39 gain
9 q12 68164115 68282615 -0.3876 0.005926 16.026 14.248 0.112428 -3.448 A1 loss
9 q12 68221319 68447264 -0.3765 0.037569 32.902 37.234 0.112428 -3.349 A1 loss
12 q13.13 52541438 52732799 0.4585 0.009104 79.974 128.2 0.111086 4.1276 A39 gain
12 q13.13 52695946 52866729 0.609 0.008809 114.9 273.57 0.111086 5.4823 A39 gain
12 q13.2 53041821 53231620 0.3898 0.026215 79.703 103.39 0.111086 3.5093 A39 gain
12 q23.3 106831834 106997898 -0.3259 0.0319 37.869 31.34 0.07167 -4.547 A75 loss
12 q23.3 106899825 107062279 -0.3327 0.036087 49.144 20.44 0.07167 -4.642 A75 loss
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15 q24.1 71985268 72141641 0.4458 0.001785 27.509 52.143 0.111086 4.0131 A39 gain
15 q24.1 72244696 72412336 -0.3799 0.028438 121.92 179.79 0.111086 -3.419 A39 loss
16 q13 55095980 55251063 0.3883 0.006653 68.105 163.08 0.111086 3.4951 A39 gain
16 q13 55211316 55369561 0.5844 0.015712 44.675 141.42 0.111086 5.2609 A39 gain
19 p13.12 14015002 14153121 0.2576 0.017678 42.295 45.186 0.07167 3.5947 A75 gain
19 p13.12 14069923 14245943 0.254 0.034706 49.545 44.306 0.07167 3.5439 A75 gain  
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Clone Name
Chr 
No.
BP Start 
(UCSC Mar 
2006)
BP End 
(UCSC Mar 
2006)
Ratio 
(Normalized 
Cy3/Cy5 
Log2 Ratio) 
Standard 
Deviation
SNR 
Ch1 
(595)
SNR 
Ch2 
(685)
SDauto 
(standard 
diviation 
of the 
ratios of 
each 
probe 
from chr 1-
22)
Thresh 
Score 
(Ratio/SD
auto)
Sample 
(1 color 
/ 
sample)
RP11-465B22 1 918163 1046699 0.239257 0.039818 22.04 23.88 0.066748 3.584482 A26
RP11-25A21 1 60807944 60980338 0.366584 0.034681 14.54 12.39 0.073771 4.969216 A137
RP11-212D5 1 150227817 150404751 0.373318 0.06219 61.24 134 0.111086 3.360622 A39
CTD-2003B3 1 204676883 204837914 0.257326 0.01329 84.67 88.31 0.066748 3.855187 A26
RP11-196C8 2 13032063 13188099 -0.238977 0.013979 35.19 24.53 0.066748 -3.58029 A26
RP11-723F23 2 14978618 15161195 0.549819 0.061044 12.69 16.76 0.073771 7.453051 A137
RP11-526C24 2 17558392 17595292 -0.257904 0.030754 90.25 76.26 0.07167 -3.59849 A75
RP11-117K20 3 159315572 159494764 0.27218 0.025486 85.08 62.14 0.07167 3.797684 A75
RP11-694E12 3 193655933 193832580 -0.454193 0.002862 109.6 82.12 0.07167 -6.33728 A75
RP11-141L5 4 819328 983918 0.32789 0.001193 20.86 21.56 0.066748 4.912357 A26
RP11-565M6 4 1530742 1691087 0.222639 0.034934 26.53 22.75 0.066748 3.335516 A26
RP11-448F22 4 2384072 2472983 0.332472 0.006866 23.86 26.81 0.073771 4.506812 A137
RP11-444J4 4 2475663 2659104 0.337627 0.002179 19.32 25.11 0.073771 4.57669 A137
RP11-431J16 4 21912514 22118512 0.382154 0.042181 10.92 13.89 0.073771 5.180274 A137
RP11-134M4 4 90847963 91018998 -0.550377 0.009356 44.23 51.05 0.111086 -4.95451 A39
RP11-659P17 4 97390836 97583629 0.484092 0.020737 97.36 195.2 0.111086 4.357813 A39
RP11-637I24 4 164173596 164206678 0.44381 0.038487 34.38 83.38 0.111086 3.995193 A39
RP11-14K14 4 190673393 190811644 0.398252 0.08705 113.6 202.5 0.111086 3.585078 A39
RP11-656C20 5 350722 447421 0.251496 0.017311 64.23 58.45 0.066748 3.767843 A26
RP11-161F13 5 1562894 1724268 -0.255112 0.013584 18.61 14.81 0.06782 -3.7616 A118
RP11-778E14 5 2592645 2774473 0.289887 0.062522 21.96 25.17 0.073771 3.929552 A137
RP11-99E23 5 174208465 174386441 -0.428273 0.083377 44.96 38.91 0.111086 -3.85533 A39
RP11-26H18 6 7545199 7735839 0.353082 0.023407 28.15 29.93 0.100303 3.520154 A51
RP11-346C16 6 110941778 111130824 0.28682 0.001887 11.04 13.81 0.073771 3.887978 A137
CTD-2310D7 6 113915311 114052447 -0.350276 0.087168 14.87 11.19 0.06782 -5.16479 A118
RP11-403C11 6 114313227 114352792 -0.257576 0.030125 83.23 69.69 0.066748 -3.85893 A26
CTD-2260L17 7 797562 898228 0.226066 0.022829 42.21 43.15 0.066748 3.386858 A26
CTD-2380A4 7 15155609 15320915 0.242054 0.010675 10.6 10.46 0.066748 3.626386 A26
RP11-455J15 7 16700151 16863920 0.318534 0.012703 15.96 16.92 0.073771 4.317876 A137
RP11-818I12 7 124755570 124943364 0.28215 0.041623 17.91 17.16 0.066748 4.227093 A26
RP11-674O21 8 3049068 3251231 0.429 0.015461 48.48 116.5 0.111086 3.861873 A39
RP11-652N4 8 4901876 5127620 0.240296 0.061576 74.88 55.14 0.07167 3.352811 A75
RP11-102I24 10 13089369 13228260 0.251713 0.015452 91.26 94.58 0.066748 3.771094 A26
RP11-818P1 10 42987824 43202215 0.281415 0.002531 10.33 11.61 0.074813 3.761579 A8
RP11-30N1 10 51121592 51195063 -0.289387 0.005939 17.06 13.7 0.06782 -4.26699 A118
Appendix 3: Table A3. CNVs Found in ACRD and Our Study
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RP11-296M15 11 133545363 133721889 0.271078 0.019537 71.41 71.26 0.066748 4.061215 A26
RP11-440N2 12 36720939 36889175 0.405225 0.054953 16.72 21.19 0.073771 5.493012 A137
RP11-26G8 12 57636373 57812533 0.362373 0.044189 18.94 20.3 0.073771 4.912133 A137
RP13-552N19 12 130837437 130869768 0.403183 0.086379 10.94 28.74 0.111086 3.629467 A39
RP11-563G5 13 18014607 18190654 0.49662 0.020139 111.7 110 0.111086 4.47059 A39
RP11-51H10 13 113492713 113658045 0.489403 0.042209 42.72 92.72 0.111086 4.405623 A39
RP11-520H13 14 64706822 64880159 0.264777 0.022368 18.64 17.34 0.07167 3.694391 A75
RP11-218L8 14 86490679 86613015 -0.387777 0.024405 26.08 29.42 0.112428 -3.44911 A1
RP11-607H20 15 18273500 18473311 -0.251218 0.005564 14.47 10.05 0.074813 -3.35795 A8
RP11-641K15 15 18781625 18946020 -0.248226 0.002765 24.74 23.85 0.06782 -3.66007 A118
RP11-403L7 15 18898414 19048601 -0.385608 0.009341 255.3 386.6 0.111086 -3.47126 A39
RP11-768D20 15 21886511 22055073 -0.38372 0.022012 18.81 20.56 0.112428 -3.41303 A1
CTD-2315M12 15 24567294 24683390 0.434072 0.004535 37.98 33.56 0.111086 3.907531 A39
RP11-561P13 15 26135317 26310601 -0.245656 0.048374 18.28 15.66 0.06782 -3.62218 A118
RP11-6L23 15 71985268 72141641 0.445803 0.001785 27.51 52.14 0.111086 4.013134 A39
RP11-775D1 15 72244696 72412336 -0.379857 0.028438 121.9 179.8 0.111086 -3.41949 A39
RP11-605N4 16 55095980 55251063 0.388252 0.006653 68.11 163.1 0.111086 3.495058 A39
RP11-343H19 16 55211316 55369561 0.584413 0.015712 44.68 141.4 0.111086 5.260906 A39
RP11-798C7 17 76834696 77076142 0.248783 0.04408 13.98 22.26 0.07167 3.471229 A75
RP11-453P5 18 56301614 56482301 0.244348 0.056018 50.52 55.02 0.07167 3.409348 A75
RP11-711F2 18 71337342 71520536 0.238207 0.045352 10.43 11.52 0.06782 3.512341 A118
RP11-703H17 18 74556232 74771957 0.383839 0.051755 34.16 81.72 0.111086 3.455332 A39
RP11-7H17 18 75216360 75402240 0.256705 0.035492 54.96 54.6 0.066748 3.845883 A26
RP11-543F7 19 33742778 33936080 0.331168 0.027284 81.34 58.75 0.07167 4.620734 A75
RP11-705C4 19 60715146 60850444 0.241451 0.025361 26.32 26.44 0.07167 3.368927 A75
RP11-476I15 20 62263781 62434320 0.26224 0.001918 34.08 32.49 0.066748 3.928807 A26
RP11-652F11 22 18002150 18171498 0.291579 0.020793 72.26 53.67 0.07167 4.068355 A75
RP11-799D2 22 46893547 47064651 0.33546 0.000556 29.09 31.35 0.100303 3.344466 A51
RP11-423E19 22 49413876 49518700 0.241691 0.029247 56.17 33.55 0.066748 3.620947 A26
RP11-297F13 X 48575765 48734088 0.349604 0.008873 52.79 65.63 0.07167 4.877968 A75
RP11-211H10 X 49201123 49376616 -0.228992 0.093953 17.52 14.12 0.06782 -3.37647 A118
RP11-201O16 1 241113402 241143060 -0.377712 0.003692 29.14 13.37 0.111027 -3.40198 A1
RP11-633H24 2 154895951 155104293 0.252524 0.034344 4.399 6.016 0.071866 3.513817 A118
RP11-719O1 2 165653881 165842181 0.27515 0.059472 9.813 10.68 0.076899 3.57807 A137
RP11-806C2 3 1841954 2043596 0.240232 0.007984 8.316 12.33 0.071866 3.342777 A118
RP11-655G22 3 193133121 193305756 0.264123 0.044765 16.05 8.214 0.076899 3.434674 A137
RP11-72I14 4 2716373 2926405 0.412427 0.095637 3.812 3.715 0.076899 5.36323 A137
RP11-18O22 4 117414505 117570802 0.240949 0.008945 70.64 68.06 0.066893 3.602006 A26
CTD-2011O21 4 191039899 191138136 -0.371553 0.011956 50.38 28 0.111027 -3.34651 A1
RP11-263G17 5 39200686 39246329 -0.40495 0.026786 3.098 3.662 0.111027 -3.64731 A1
CTD-2075G19 5 103890873 104011391 0.319472 0.016983 6.677 7.662 0.071866 4.445384 A118
RP11-144H10 5 120001738 120179752 0.405011 0.041323 6.166 6.076 0.071866 5.635641 A118
RP11-281H9 5 128933631 129091165 0.443518 0.022903 6.557 3.874 0.071866 6.171458 A118
RP11-625D22 6 14164567 14370368 0.313224 0.040759 8.809 11.92 0.071866 4.358445 A118
RP11-278D12 6 113973438 114122489 -0.453926 0.066488 12.55 8.891 0.071866 -6.31628 A118
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RP11-324H19 6 125778192 125951756 0.36266 0.068032 4.833 4.766 0.076899 4.716056 A137
RP11-299O9 7 84194243 84365508 0.261287 0.078691 5.634 4.704 0.071866 3.635753 A118
RP11-1279M16 7 88320492 88498710 0.46968 0.046197 4.25 4.237 0.076899 6.107752 A137
RP11-86H8 7 110936386 111097114 -0.47501 0.009298 16.87 9.816 0.071866 -6.60966 A118
RP11-651O22 8 43028640 43224677 0.359587 0.047851 4.669 3.746 0.071851 5.004621 A75
RP11-467K20 9 21965732 22150198 0.444524 0.046725 7.135 9.093 0.076899 5.780621 A137
RP11-730N17 9 23690948 23798886 -0.452101 0.026159 6.635 5.62 0.131551 -3.4367 A14
RP11-603E21 9 29426014 29599173 0.331981 0.006754 5.38 4.587 0.076899 4.317104 A137
RP11-76C9 9 31283693 31430872 -0.244388 0.073384 5.46 4.681 0.071866 -3.40061 A118
RP11-730A19 10 13062307 13253628 -0.305214 0.007694 6.934 8.734 0.071866 -4.24699 A118
RP11-745A18 10 53025431 53219133 0.247577 0.068874 7.317 6.843 0.071866 3.444981 A118
RP11-3D5 10 57052410 57216834 -0.258206 0.031341 5.922 3.949 0.076899 -3.35773 A137
RP11-318J23 10 65711959 65891133 0.583614 0.081476 4.356 5.302 0.076899 7.589357 A137
RP11-138D23 13 66378445 66542967 -0.299936 0.047363 4.869 3.511 0.076899 -3.90039 A137
RP11-745K2 14 75867497 76087405 0.435484 0.014216 8.298 14.74 0.100216 4.345454 A51
RP11-418F16 15 83235499 83414337 0.266466 0.027598 15.93 7.079 0.076899 3.465143 A137  
